



The Peer Reviewed Management Source for Lab Professionals since 1969

CE

sPLA₂-IIA

The next step in the cardiac testing panel

TRIGLYCERIDES

TOTAL
CHOLESTEROL

LDL-C

HDL-C

Revenue cycle management

Polymerase chain reaction

Crisis in Venezuela

EXECUTIVE SNAPSHOT

Lior Hod
ELLKAY

Chief Culture Officer
Founder & President



MAKING A SPLASH WITH LIQUID LINEARITY AND DAILY QC

Over
120
Analytes
Available



AUDIT[®]

MicroControls[™]

INTRODUCING A NEW ADDITION TO OUR LINE OF LIQUID LINEARITY LINEARITY FLQ VITAMIN D FOR ORTHO VITROS



Levels: Five
Format: Frozen Liquid
Package Size: 5 x 1 mL
Open Vial Stability: 7 days when stored at 2-8°C
Analytes: Vitamin D
Order Number: K910M-5

Providing value to our customers through:

- A broad line of superior quality universal & analyzer specific products.
- Personalized technical support from our experienced laboratory professionals.
- AUDITOR QC, a free and easy to use online data reduction service providing “instant reports”.



AUDIT[®]
MicroControls

Small but **mighty** molecular.



Fast

30-50 min.
to results

Easy

Simple
procedure

Convenient

Run 1-12 different
tests in a single run

CLIA

Moderately
complex

Women's Health

GBS (Group B Strep)
HSV 1+2/VZV
Trichomonas

Respiratory

Bordetella Complete
(*B. pertussis* and
B. parapertussis)
GAS (Group A Strep)
Influenza A+B
Respiratory Viral Panel
(Flu A, Flu B, RSV, hMPV)
RSV + hMPV
Strep Complete
(Strep A, C/G)

HAI

C. difficile

The Accurate. Sustainable.
Molecular Solution.

Join us for a 1 hour webinar

Four URI seasons in real-time.

John Tamerius, Ph.D. will recap the 2018/2019 respiratory season, discussing highlights, surprises and takeaways using Quidel's respiratory mapping available through Virena.

May 15, 2019 at 1:00 p.m. EDT

To sign up go to: bit.ly/2G2Qzfc




Solana®
with the
Power of Virena

Visit Quidel in Booth #717 at the ASM Clinical Virology Symposium to learn more!



The Peer Reviewed Management Source for Lab Professionals since 1969

8



16



24



38



44



- 4 From the editor
- 6 The observatory

CONTINUING EDUCATION

- 8 **sPLA₂-IIA—the next step to enhancing your cardiac testing panel**
By Rebecca Kirby
- 14 **CE Test**
Tests can be taken online or by mail. See page 14 for testing and payment details.

CLINICAL ISSUES

- 16 **Chemistry instrumentation—a critical need in Venezuelan labs**
By Vanessa Hawrylak, MS, MT(ASCP)

SPECIAL FEATURE

- 20 **PCR: a versatile tool—from detecting genetic diseases and cancers to monitoring stability after bone marrow transplants**
By Teresa Snyder-Leiby, PhD

LAB MANAGEMENT

- 24 **Enterprise vs. purpose-built lab RCM systems**
By Lale White and David Nichols

EDUCATION

- 28 **Diamond-Blackfan anemia: a familial case with emphasis on multi-diagnostic approach to diagnosis and treatment**
By Floyd Josephat, EdD, MT(ASCP) and Katrina Goff, MS, MLS(ASCP)

THE PRIMER

- 34 **Quantitative trait loci—uncovering genes for continuously variable traits**
By John Brunstein, PhD

PRODUCT FOCUS

- 38 **Analyzers**

MARKETPLACE

- 42 **Spotlights**
- 43 **Advertiser index**

EXECUTIVE SNAPSHOT

- 44 **A conversation with Lior Hod, ELLKAY's Beekeeper, Chief Culture Officer, Founder & President**
By Janette Wider, Editor



THE FUTURE OF PROFICIENCY TESTING

Save Time and Improve Accuracy With API DataDirect



American
Proficiency
Institute

API's innovative data upload process eliminates clerical errors, the number one cause of proficiency testing failures.

Want to try us before committing? Call today for a free test drive and itemized cost comparison.

(800) 333-0958 | api-pt.com

Accepted by: CAP, CMS, COLA, TJC

ISO Accredited by A2LA: Cert. #3094.01

Networking at KnowledgeLab 2019



By Lisa Moynihan
Editor

The 2019 Clinical Laboratory Management Association (CLMA) annual conference was held in Grapevine, TX this year. The CLMA KnowledgeLab is one of my favorite conferences to attend based on several reasons: its intimate size, its quality vendors, and its regular attendees (a special shout-out to my SAFMLS friends!). I've highlighted a few of my favorites, below:

In its fourth year attending CLMA, the Society of American Federal Medical Laboratory Scientists (SAFMLS) is a non-profit organization established in 1971. Membership is open to qualified military (active and reserve), Public Health Service, and Veteran's Administration personnel, and their affiliated scientists that support

healthcare via laboratory research and evaluation. Their primary objective is, "maintaining and enhancing high professional standards through improved laboratory policies and technology in support of the healthcare delivery systems."¹ Explore SAFMLS, here: <https://www.safmls.org/>.

Always on the lookout for something interesting, I happened upon Bobby Tschann, US-Fungitell Account Manager at the Associates of Cape Cod, Inc. Their tagline is, "Your Endotoxin & Glucan Experts." They were displaying their Fungitell Assay (FDA-cleared and CE marked) for rapid invasive fungal infection (IFI) screening. Their assay is manufactured using horseshoe crab blood. (Interesting fact: horseshoe crabs use hemocyanin to carry oxygen through their blood. Because of the copper present in hemocyanin, their blood is blue.) They have a cool Horseshoe Crab Sustainability Project which focuses on supporting fisheries worldwide and ensuring the genetic diversity of the horseshoe crab. Learn more, here: <http://www.acciusa.com/>.


If you've ever had to undergo an invasive colonoscopy, you'll appreciate this next product—Epi proColon. Epi proColon is an FDA approved colon cancer screening blood test. Marketing Director David Bull explained to me that their goal is addressing non-compliant patients (those unwilling or unable to be screened by stool-based, direct visualization, and/or serology tests). In a clinical study, 99.5 percent of twice non-compliant persons completed the blood test.² Discover more, here: <https://www.epiprocolon.com/us/>.

I made a new acquaintance at the Center for Surveillance, Epidemiology, and Laboratory Services (CSELS), a Division of Laboratory Systems (DLS) at the Center for Disease Control (CDC) in Atlanta, Georgia. James Bratton, fellow editorial guru and Japanophile, exposed me to their government funded programs, including laboratory eLearning tools, courses, and resources—many of which are FREE. Browse their full catalog of lab-centric opportunities at <https://www.cdc.gov/csels/dls/> and DLS training courses at <https://www.cdc.gov/labtraining/>.

Last, but not least, I connected with the dedicated team at Visiun, among them, Technical Support Specialist, Vanessa Hawrylak. With Visiun's support, Vanessa is seeking a lab who can donate a waived chemistry analyzer to help build a small STAT lab in her crisis-stricken home country of Venezuela. Any other lab supplies that are no longer needed are also being accepted. Read more about Vanessa's honorable efforts in our chemistry feature found on page 16.

Looking forward to seeing old and new faces next year in Louisville, Kentucky for KnowledgeLab 2020 from March 29 – April 1, 2020!

References available at mlo-online.com.



MEDICAL LABORATORY OBSERVER Vol.51, No.6

Publisher/Executive Editor

Kristine Russell
krussell@mlo-online.com

Editor

Lisa Moynihan
Imoynihan@mlo-online.com

Editor

Janette Wider
jwider@mlo-online.com

Graphic Artist

Patti Connors
pconnors@endeavorb2b.com

Audience Development/List Rentals

Laura Moulton
lmoulton@endeavorb2b.com

Ad Traffic Manager

Norma Machado
nmachado@endeavorb2b.com

eProduct Coordinator

Mary Haberstroh
mhaberstroh@endeavorb2b.com

ADVERTISING

East Coast/Midwest Sales (except IL)

Classified/Recruitment Advertising

Carol Vovcsko
(941) 321-2873
cvovcsko@mlo-online.com

South/West Coast/Illinois Sales

Lora Harrell
(941) 328-3707
lharrell@mlo-online.com

MLO EDITORIAL ADVISORY BOARD

John Brunstein, PhD, Biochemistry (Molecular Virology)

President & CSO
PathoID, Inc., British Columbia, Canada

John A. Gerlach, PhD, D(ABHI)

Laboratory Director
Michigan State University, East Lansing, MI

Barbara Strain, MA, SM(ASCP)

Director, Supply Chain Analytics
University of Virginia Health System, Charlottesville, VA

Jeffrey D. Klausner, MD, MPH

Professor of Medicine and Public Health
Division of Infectious Diseases: Global Health, Dept. of
Epidemiology, David Geffen School of Medicine,
Karen and Jonathon Fielding School of Public Health,
University of California Los Angeles, CA

Susan McQuiston, JD, MT(ASCP), SCy(ASCP)

Instructor, Biomedical Laboratory Diagnostics Program
Michigan State University, East Lansing, MI

Donna Beasley, DLM(ASCP)

Director
Huron Healthcare, Chicago, IL

Anthony Kurec, MS, H(ASCP)DLM

Clinical Associate Professor, Emeritus
SUNY Upstate Medical University, Syracuse, NY

Suzanne Butch, MLS(ASCP)CM, SBB^{CM}, DLM^{CM}

Freelance Consultant, Ann Arbor, MI

Paul R. Eden, Jr., MT(ASCP), PhD

Lt. Col., USAF (ret.)
(formerly) Chief, Laboratory Services
88th Diagnostics/Therapeutics Squadron
Wright-Patterson AFB, OH

CORPORATE TEAM



Chris Ferrell, CEO

Scott Bieda, EVP, CRO | June Griffin, CMO

Tracy Kane, VP, General Counsel, HR | Patrick Rains, COO

Angela Rex, VP Accounting | Kristine Russell, EVP

2477 Stickney Point Rd., Suite 221B Sarasota, FL 34231

Phone: (941) 388-7050 Fax: (941) 388-7490

www.mlo-online.com



MLO - MEDICAL LABORATORY OBSERVER

(ISSN: 0580-7247). Published monthly, with an additional issue in August, by Endeavor Business Media, LLC, 2477 Stickney Point Rd., Suite 221B, Sarasota, FL 34231 (941) 388-7050. Subscription rates: \$127.60/year in the U.S.; \$154.85 Canada/Mexico; Intl. subscriptions are \$221.43/year. All issues of MLO are available on microfilm from University Microfilms International, Box 78, 300 N. Zeeb Rd., Ann Arbor, MI 48106. Current single copies (if available) \$15.40 each (U.S.); and \$19.80 each (Intl.). Back issues (if available) \$17.60 each (U.S.); \$22.00 each (Intl.). Payment must be made in U.S. funds on a U.S. bank/branch within the continental U.S. and accompany request. Subscription inquiries: subscriptions@endeavorb2b.com. MLO is indexed in the Cumulative Index for Nursing and Allied Health Literature and Lexis-Nexis. MLO Cover/CE, Clinical Issues, and Lab Management features are peer reviewed. Title® registered U.S. Patent Office. Copyright® 2018 by Endeavor Business Media, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage-and-retrieval system, without written permission from the publisher. Office of publication: Periodicals Postage Paid at Nashville, TN 37209 and at additional mailing offices. Postmaster: Send address changes to Omeda (MLO Medical Laboratory Observer), PO Box 3257, Northbrook, IL 60065-3257. Printed in U.S.A.



MAXIMIZE YOUR LABORATORY'S TESTING CAPABILITIES WITH THE RX DAYTONA+ AND RX IMOLA

Renowned for quality and reliability, the RX daytona+ and RX imola clinical chemistry analyzers benefit from the world leading RX series test menu comprising; routine chemistries, specific proteins, lipids, therapeutic drugs, drugs of abuse, antioxidants and diabetes testing. The RX daytona+ is capable of a throughput of 450 tests per hour and the RX imola is capable of a throughput of 560 tests per hour with STAT capabilities.



LEADING TESTING MENU

...

The RX series test menu comprises over 113 clinical chemistry assays with 22 more tests than the nearest competitor.



HIGH PERFORMANCE AND UNIQUE REAGENTS

...

Placing precision, accuracy and reliability at the forefront, the RX series test menu includes a wide range of high performance and novel assays including HbA1c testing capabilities.



SAVING TIME AND COSTS IN THE LABORATORY

...

The RX daytona+ and RX imola guarantee real cost savings through consolidation of routine and specialized tests onto a single platform with unrivalled uptime and performance.



+1 304 728 2890 | Toll Free: 866 472 6369 | radox.com/rxseries

Product availability may vary from country to country. Some products may be for Research Use Only.
For more information on product application and availability, please contact your local Randox Representative.

FAST FACTS

PCOS

Polycystic ovary syndrome (PCOS) is caused by an imbalance of reproductive hormones that creates problems in the ovaries and is one of the most common causes of infertility. With PCOS, the egg may not develop properly, or it may not be released during ovulation.

1 in 10

women of childbearing age are affected by PCOS.

5-10 percent

of women between 15 and 44 have PCOS.

5 million

is the number of women in the U.S. that have PCOS.

20s and 30s

is the age most women discover they have PCOS.

70 percent

of women have hirsutism (male-pattern hair growth) as a symptom.

10 percent

loss of body weight encourages regular menstrual cycles, improving successful fertilization.

2 of these 3

symptoms determine a PCOS diagnosis: irregular periods or no periods as a result of anovulation; abnormal male hormone levels resulting in excess hair, acne, or thinning scalp hair; and/or multiple small ovarian cysts.

• **Sources:** <https://www.womenshealth.gov/a-z-topics/polycystic-ovary-syndrome>, <https://www.cdc.gov/diabetes/library/spotlights/pcos.html>

Tickborne illness

CDC offers new resource for tick season. Tick season is here and that means it's time once again for people to protect themselves and their loved ones (including pets) from tick bites. The Centers for Disease Control and Prevention (CDC) has an updated digital press kit available with the latest information about the increasing number of reported tickborne illnesses, newly discovered disease-causing germs, expanding ranges of ticks, and a novel tick species recently found in the United States.

Last year, nearly 60,000 cases of tickborne disease were reported to the CDC by state health departments and the District of Columbia. Though it can't be predicted how bad any particular season will be, it is known that reducing exposure to ticks is the best defense against Lyme disease, Rocky Mountain spotted fever, and other tickborne infections.

The CDC has more information available here: <https://www.cdc.gov/media/dpk/diseases-and-conditions/lyme-disease/index.html>.

Infectious disease

Decline in measles vaccination is causing a preventable global resurgence of the disease. In 2000, measles was declared to be eliminated in the United States. Today, however, the U.S. and many other countries are experiencing concerning outbreaks of measles because of declines in measles vaccine coverage. Without renewed focus on measles vaccination efforts, the disease may rebound in full force, according to the *New England Journal of Medicine* by infectious diseases experts at NIAID, part of the NIH, and the Penn State University College of Medicine's Milton S. Hershey Medical Center.

Measles is an extremely contagious illness transmitted through respiratory droplets and aerosolized particles that can remain in the air for up to two hours. Most often seen in young children, the disease is characterized by fever, malaise, nasal congestion, conjunctivitis, cough, and a red, splotchy

rash. Most people with measles recover without complications within a week. However, for infants, people with immune deficiencies, and other vulnerable populations, the consequences of a measles infection can be severe. Rare complications can occur, including pneumonia, encephalitis, other secondary infections, blindness, and even death. Before the measles vaccine was developed, the disease killed between 2 and 3 million people annually worldwide. Today, measles still causes more than 100,000 deaths globally each year.

Measles can be prevented with a vaccine that is both highly effective and safe. Each complication and death related to measles is a "preventable tragedy that could have been avoided through vaccination," the authors write. Some people are reluctant to vaccinate their children based on widespread misinformation about the vaccine. For example, they may fear that the vaccine raises their child's risk of autism, a falsehood based on a debunked and fraudulent claim. A very small number of people have valid medical contraindications to the measles vaccine, such as certain immunodeficiencies, but almost everyone can be safely vaccinated.

When levels of vaccine coverage fall, the weakened umbrella of protection provided by herd immunity—indirect protection that results when a sufficiently high percentage of the community is immune to the disease—places unvaccinated young children and immunocompromised people at greater risk. This can have disastrous consequences with measles. The authors describe a case in which a single child with measles infected 23 other children in a pediatric oncology clinic, with a fatality rate of 21 percent.

If vaccination rates continue to decline, measles outbreaks may become even more frequent, a prospect the authors describe as "alarming." This is particularly confounding, they note, since measles is one of the most easily prevented contagious illnesses. In fact, it is

possible to eliminate and even eradicate the disease. However, they say, achieving this goal will require collective action on the part of parents and healthcare practitioners alike.

Leadership

Strong laboratory leaders—a key asset for global disease control. Laboratories play an essential role in the detection, diagnosis, prevention, and control of diseases. To strengthen this role, ECDC (European Centre for Disease Prevention and Control) and five partner organizations have developed the Global Laboratory Leadership Program (GLLP) to support and sustain national laboratory systems under a One Health approach.

Reliable laboratory services continue to be limited in many low- and middle-income countries. Although there have been examples of effective laboratory responses to outbreaks, a well-documented number of such events have shown how a lack of robust laboratory systems can impede disease control and prevention efforts.

To strengthen laboratory systems and address gaps in laboratory leadership competency across sectors, the GLLP was established. ECDC collaborated with five partners to develop the GLLP: Association of Public Health Laboratories (APHL); Centers for Disease Control and Prevention (CDC); Food and Agriculture Organization of the United Nations (FAO); World Organization for Animal Health (OIE); and World Health Organization (WHO).

The GLLP targets professionals working in human and animal health laboratories, as well as laboratories with public health functions such as environmental, agricultural, food, chemical, and aquatic laboratories.

The development of the GLLP represents the first global effort involving input and support from multiple organizations and institutions to create a core set of competencies for laboratory leaders working in support of health systems and a related flexible and adaptable learning package.

HIV

Novel antibody may suppress HIV for up to four months.

Regular infusions of an antibody that blocks the human immunodeficiency virus (HIV) binding site on human immune cells may have suppressed levels of HIV for up to four months in people undergoing a short-term pause in their antiretroviral therapy (ART) regimens, according to a report published online in *The New England Journal of Medicine*. Results of the Phase 2, open-label study indicate the antibody, known as UB-421, was safe and did not induce the production of antibody-resistant HIV. The study was supported in part by NIAID, a component of the NIH, and United Biopharma.

The study was conducted in Taiwan and led by Chang Yi Wang, PhD, Chief Scientific Officer and Chairperson of United BioPharma. Twenty-nine volunteers with well-controlled HIV discontinued their normal regimens of daily oral ART at the time of their first infusion or one week later, depending on their ART regimen. Fourteen study participants received eight regular weekly infusions of UB-421, while 15 received eight higher-dose infusions every other week. At the end of the eight- or 16-week treatment period, all volunteers restarted their previous ART regimen and were evaluated in follow-up visits up to eight weeks later. Apart from a single participant who discontinued the study because of a mild skin rash, volunteers in both groups maintained HIV suppression throughout the treatment period in the absence of ART.

Previous experimental infusions of broadly neutralizing antibodies (bNAbs) have suppressed HIV for about two weeks by targeting proteins on the virus itself, but the rapid mutation rate of HIV induces antibody-resistant strains that render the treatment ineffective. UB-421 theoretically avoids this possibility by blocking a stable human protein that HIV uses to infect T cells.

Indeed, resistance to UB-421 was not seen in this study. Because the small study did

not include a comparator group receiving a placebo infusion, further studies have been planned in Taiwan and Thailand to evaluate the safety and efficacy of UB-421 as a treatment for HIV.

HPV

HPV rates for women under 40 increasing, putting them at higher risk of related cancers.

Human papillomavirus (HPV) infection rates are increasing in women born after 1980 who did not receive the HPV vaccine—putting them at higher risk for HPV-related cancers, according to a University of Michigan study.

While more than 90 percent of HPV-related cancers are preventable, HPV causes more than 40,000 cases of cancer in the U.S. each year, including cervical, oropharyngeal, anal, and other genital cancers. The CDC estimates that at least half of all sexually active men and women will acquire HPV in their lifetime.

Because testing for genital HPV started in 2003 for women and in 2013 for men, there are no direct measurements of how HPV incidence and prevalence have changed over the past decades—before the vaccine became available for women in 2006 and for men in 2009.

Researchers said previous analyses focused only on measures of current HPV infection (viral DNA) or past HPV infection (antibodies), producing sometimes competing results, making it difficult for experts to predict current and future trends.

For their analysis, researchers developed a model that uses both HPV infection and past infection data, as well as mathematical representations of the underlying mechanisms of infection, recovery, and the generation of antibodies, to paint a better picture of HPV prevalence in the present and past.

Their model indicates that while there may be a substantial increase in HPV prevalence in more recent birth cohorts, HPV vaccination may ultimately control adverse HPV-related outcomes, including genital warts and cancer. Questions still remain, such as why there is a peak in HPV infection among 45-to-55-year-olds. 

sPLA₂-IIA—the next step to enhancing your cardiac testing panel

By Rebecca Kirby

Cardiovascular disease (CVD) is the number one cause of death globally, with an estimated 17.7 million people dying each year. This figure represents approximately 31 percent of all global deaths.¹ Worryingly, this figure is set to increase to over 23.6 million by 2030. These startling statistics highlight the urgent need for better and earlier identification of at-risk individuals; this is especially true as many CVD cases can be prevented with appropriate lifestyle changes. This article will discuss the utility of sPLA₂-IIA, a novel biomarker for use in CVD risk assessment.

Traditional and routinely run biomarkers for CVD risk include lipid assays such as Total Cholesterol, HDL Cholesterol (HDL-C), LDL Cholesterol (LDL-C), and Triglycerides. There is, however, a growing body of research and evidence indicating that additional risk assessment biomarkers need to be considered. Conventional risk assessment markers like those mentioned previously detect a mere 20 percent of all CVD patients. As the prevalence of CVD continues to rise worldwide, the need for reliable risk markers has never been more important.

sPLA₂-IIA has been proven to have clinical utility as a biomarker of inflammation. Inflammation is a process by which the body launches an attack utilizing our white blood cells. This response results in redness and swelling to either eliminate the pathogen or rid the body of an intruder.^{2,3} Inflammation is a common response in many disease states, in some cases the body's immune system triggers an inflammatory response when there are no invaders to fight off. Inflammation is also associated with CVD. Although not a direct cause of CVD, inflammation is common in heart disease and stroke patients and is thought to be a sign of an atherogenic response. It is believed that in CVD the body perceives the plaque as abnormal or foreign and in response the body tries to prevent the plaque from entering the blood.³ However, in some circumstances, the plaque may rupture and come in contact with the blood triggering clot formation.³

Early risk assessment helps to reduce the risk of a cardiac event occurring. Identifying those at highest risk of CVD and ensuring they receive appropriate treatment can prevent premature death.⁴ Early risk assessment is particularly important in people who present with one or more risk factors including hypertension, diabetes, or hyperlipidemia. As stated before, by 2030 it is estimated that almost 23.6 million people will die from CVD, with heart disease and stroke projected to remain the leading causes of death.⁴ This provides further confirmation that early diagnosis is an essential step in reducing the number of individuals affected.

The financial burden that CVD places on health services makes the development of a diagnostic biomarker even more essential. sPLA₂-IIA, a member of the secretory phospholipase A₂ family, has been found to have clinical utility as an inflammation biomarker specifically in the diagnosis of CVD risk. The addition of sPLA₂-IIA could compliment the labs existing cardiac risk panel, providing a different outlook and method of assessing cardiac concerns in patients.

Biological significance

The phospholipase A₂ family encompasses a wide range of enzymes that are all capable of hydrolyzing the sn-2 ester bond of a natural phospholipid substrate. This reaction produces lysophospholipids and free fatty acids. Despite similar structural features, catalytic mechanisms, and evolutionary relationships, the superfamily of PLA₂




Figure 1: Inflammation⁵

Earning CEUs

See test on page 14 or online at www.mlo-online.com under the CE Tests tab.

LEARNING OBJECTIVES

Upon completion of this article, the reader will be able to:

1. Discuss disease and mortality statistics of cardiovascular disease (CVD).
2. Recall the new biomarker being studied for CVD and its utility in early risk assessment.
3. Describe the chemical process by which sPLA₂-IIA acts on the coronary artery wall.
4. Discuss other diseases that sPLA₂-IIA is being used on.

enzymes is divided into fifteen separate groups and a number of subgroups.⁵ Representing one of the groups is the secretory PLA₂ (sPLA₂) family, which consists of ten catalytic active enzymes. These enzymes share the same characteristics as the PLA₂ superfamily but have additional unique features.




Figure 2. Atherosclerosis⁶

sPLA₂-IIA

sPLA₂-IIA is the prototypic member of the group II sPLA₂ subfamily and has been shown to be induced by pro-inflammatory stimuli in a wide variety of cells and tissues. It has been found to be associated with a number of inflammatory diseases including coronary artery disease and atherosclerosis.⁵ These factors have contributed to its nickname, “inflammatory sPLA₂.”

Pro-inflammatory sPLA₂-IIA

sPLA₂-IIA can also be referred to as a bactericide and is involved in the degradation of the bacterial membrane providing a host defense mechanism against microbial infection. sPLA₂-IIA is highly cationic and has a higher affinity for anionic phospholipids, such as phosphatidylethanolamine (PE). This affinity means that sPLA₂-IIA preferentially binds to PE over phosphatidylcholine (PC). PE is a phospholipid that is abundantly found on bacterial membranes. This allows the enzyme to penetrate the cell and hydrolyze membrane phospholipids causing bacterial death.⁵

Figure 1 illustrates how sPLA₂-IIA binding to anionic phospholipids leads to its activation and promotes inflammation.⁵ The oxidation of phospholipids produces stress. This stress causes the anionic phospholipids phosphatidylserine (PS) and PE to be transported to the outer leaflet. This reaction activates cationic sPLA₂-IIA.

The higher activity of sPLA₂-IIA promotes the hydrolysis of the outer leaflet phospholipids into arachidonic acid and lysophospholipids. Through the cyclooxygenase and 5 – lipoxygenase enzymes, arachidonic acid is converted into prostaglandins, leukotrienes, and other eicosanoids. The lysophospholipids are converted into platelet-activating factors (PAFs). All four of the products produced have been linked to inflammation. Detecting the release of sPLA₂-IIA could therefore be a good starting point for the diagnosis of diseases related to inflammation.⁵

sPLA₂-IIA hydrolysis reaction

sPLA₂-IIA production of fatty acids and biologically active phospholipids plays an important role in platelet, monocyte, and endothelial activation, processes known to be critical steps in atherogenesis.⁶ Unlike traditional cardiac biomarkers used to predict adverse outcomes in patients with acute coronary syndrome (ACS), sPLA₂-IIA has been shown to act at multiple pathways involved in atherogenesis, from lipid oxidation to modulation of vascular and inflammatory cell activation and apoptosis.⁷

Key observations through research found that sPLA₂-IIA mediated modification of lipoproteins plays a role in the development of atherosclerosis. The surface of both LDL Cholesterol (LDL-C) and HDL Cholesterol (HDL-C) is surrounded by phosphatidylcholine (PC)—a type of phospholipid which has been scientifically proven to




Figure 3. Atherogenesis leading to the atherosclerosis²⁰

serve as a good extracellular target for several isoforms of sPLA₂-IIA. sPLA₂-IIA works by hydrolyzing these phospholipids resulting in the production of free fatty acids and lysophosphatidylcholine (LPC) which can generate




Figure 4. Kaplan-Meier estimates of secondary fatal and non-fatal CVD events during follow-up according to tertiles of sPLA₂-IIA mass at baseline¹³

pro-inflammatory actions, accelerating atherosclerosis.⁶ Hydrolysis of LDL-C correlates with the production of the more atherogenic, small dense LDL cholesterol (sdLDL-C) particles. The sPLA₂-IIA -processed LDL-C particles contain a large amount of lysophospholipids and exhibit the property of “small-dense” or “modified” LDL-C, which facilitates foam cell formation from macrophages. Research has shown that high levels of sdLDL-C compared to less dense, larger LDL-C increases the risk of coronary heart disease.

Figure 2 illustrates the proposed role of sPLA₂-IIA in the development of atherosclerosis. The diagram highlights the role sPLA₂-IIA has in the hydrolysis of LDL-C into the more atherogenic sdLDL-C.⁶

Comparison of sPLA₂-IIA with the traditional Lp-PLA₂ test

Lp-PLA₂ is a cardiac biomarker, sharing similarities with sPLA₂-IIA as it too is a member of the phospholipase A₂ enzyme family. Both sPLA₂-IIA and Lp-PLA₂ have associations with LDL-C. LDL-C carries Lp-PLA₂ to the coronary artery walls where it activates an inflammatory response. This process makes plaques, if present, more prone to rupture. This enzyme is associated with causing inflammation of the coronary artery walls, indicating that high levels of Lp-PLA₂ would increase the risk of a heart attack or stroke.⁸ In contrast, in blood, sPLA₂-IIA can hydrolyze LDL-C producing sdLDL-C which is highly atherogenic.⁹ sPLA₂-IIA is linked to the formation and destabilization of atherosclerotic plaques. Research has found that increased sPLA₂-IIA protein expression increases with atherosclerotic lesion development.

Figure 3 illustrates the process of atherogenesis and atherosclerosis and the formation of plaques. These are processes that both sPLA₂-IIA and Lp-PLA₂ are involved in.²⁰

Though involved in similar mechanisms, research has found that among biomarkers of inflammation sPLA₂-IIA mass improved risk discrimination for identifying patients that have an increased risk of major adverse cardiovascular

events.¹⁰ The biological role of Lp-PLA₂ has been controversial, with contradictory antiatherogenic and proatherogenic functions.⁹

Research conducted found a significant association between sPLA₂-IIA mass and diagnosis of CVD while the Lp-PLA₂ activity appeared to not be associated with CVD diagnosis. Furthermore, patients with sPLA₂-IIA at presentation in the highest quartile had a statistically higher incidence of cardiac death and myocardial infarction (MI) however, no association was observed with Lp-PLA₂ activity.¹¹ Although Lp-PLA₂ activity has been associated with some cardiovascular diseases, researchers question whether Lp-PLA₂ has clinical utility and its role as a risk prediction biomarker.¹²

Relevant studies

1. Association between type II secretory phospholipase A₂ plasma concentration and activity and cardiovascular events in patients with coronary heart disease (2009).¹³

Figure 4 provides an estimation of event free survivors over a number of days depending on the level of sPLA₂-IIA mass present in the patient. As shown in the graph, the lower line represents the patients with the highest levels of sPLA₂-IIA. The proportion of event free survivors is lower for this tertile in comparison. This proportion further confirms the importance of measuring sPLA₂-IIA for preventing secondary coronary events.

2. Lipoprotein associated phospholipase A₂ predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress (2006).^{9,14}

A study carried out by KAROLA involved measuring sPLA₂-IIA mass and sPLA₂-IIA activity in stable coronary disease. sPLA₂-IIA mass and sPLA₂-IIA activity showed a relatively good correlation ($r = 0.63$), and both measurements were significantly associated with an adverse outcome. sPLA₂-IIA mass appeared to perform better as a risk predictor than sPLA₂-IIA activity when extreme tertiles were compared.


3. Prognostic value and the changes of plasma levels of secretory type II phospholipase A₂ in patients with coronary artery disease undergoing percutaneous coronary intervention (2003).^{9,15}

A small study was carried out on patients who were angiographically proven stable coronary artery disease (CAD). Circulating levels of sPLA₂-IIA mass were higher in these patients than in control individuals. In addition, elevated baseline levels of sPLA₂-IIA were independently associated with adverse outcomes including; coronary death, MI, and coronary revascularization.

Research has shown that levels of sPLA₂-IIA increase immediately after mechanical disruption of the coronary artery plaque by percutaneous coronary intervention (PCI). A PCI is a non-surgical procedure that uses a catheter to place a stent in the blood vessels in order to open vessels that have been blocked by atherosclerosis. sPLA₂-IIA responds rapidly to the inflammatory activity in atherosclerotic arteries and plaque rupture. Also, the higher levels of sPLA₂-IIA after PCI could be used to predict risk of future coronary events.

Additional uses of sPLA₂-IIA

Scientific research has consistently highlighted the potential of sPLA₂-IIA as a risk marker for CVD. However, there is also a growing body of evidence to support the clinical use of sPLA₂-IIA as a diagnostic marker in other disease



SHORTEN TIME TO DIAGNOSIS



» THE ACCESS hsTnI ASSAY

Accuracy. Sensitivity. Speed.

Minutes matter when symptoms suggest acute myocardial infarction (AMI). Access hsTnI can speed patient decision making by identifying 94% of true AMI patients in **as little as sixty minutes after patient presentation.**

The Access hsTnI high-sensitivity troponin I assay offers better precision than standard troponin assays, rapidly detecting even very low levels of troponin to support efficient care for cardiac patients.

Speak to your ED physicians today and start on the path to better cardiac patient care.

© 2019 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

For more information, visit www.beckmancoulter.com/ami

AD-147703



» Move healthcare forward.

areas. Sepsis is a serious complication of infection and without quick treatment it can lead to multiple organ failure and death.¹⁶ Survivors of sepsis suffer from various complications that arise from organ dysfunction, which can result in severe impairment in their quality of life. The key to sepsis management relies on prompt and accurate diagnosis. This is because every hour appropriate treatment with antibiotics patient mortality increases by five to 10 percent. There has therefore been considerable effort among researchers to discover the most reliable sepsis biomarker.¹⁷

The current guidelines for sepsis diagnosis follows the Systemic Inflammatory Response Syndrome (SIRS) criteria. This involves monitoring the patients' temperature, heart rate, respiratory rate, and WBC count. Several blood tests may also be employed including procalcitonin (PCT) which is the most commonly used biomarker for the diagnosis of sepsis. The accuracy and reliability of PCT however is questionable. Research was conducted to compare different biomarkers of sepsis and their accuracy in early rule in/out of sepsis. The study involved testing 168 different biomarkers (including sPLA₂-IIA and PCT) in pediatric and adult intensive care units. Of the 168 markers tested, only five biomarkers were found to have greater than 90 percent specificity for diagnosis, this included sPLA₂-IIA but excluded PCT.¹⁸

PCT is the current diagnostic and prognostic biomarker utilized in emergency departments. Although PCT and sPLA₂-IIA are correlated, the accuracy of PCT as a biomarker alone is significantly lower than sPLA₂-IIA.¹⁸

sPLA₂-IIA has been found to demonstrate significant association with the presence of sepsis. Studies have found that sPLA₂-IIA as an early marker of sepsis carries substantial clinical significance. Although further studies are required for confirmation, this provides another potential use of this biomarker. sPLA₂-IIA has also shown clinical utility as a biomarker for chronic inflammatory conditions such as rheumatoid arthritis.

Methodology

Randox utilizes the latex enhanced immunoturbidimetric methodology in the development of the sPLA₂-IIA assay. Traditionally, ELISA-based methods were developed for the detection of sPLA₂-IIA levels. The main downfall of the ELISA method is that it is time-consuming for practical clinical diagnostic use.¹⁹ Conversely, immunoturbidimetry is the most popular methodology as it can be easily adapted for high volume testing in automated analyzers.²¹

Conclusion


CVD continues to be the leading cause of death worldwide.¹ Consequently, it is vital that superior assays, such as sPLA₂-IIA are implemented to detect the disease in its earliest stages for the early and effective implementation of treatment plans, reducing the financial burden on health care systems. As sPLA₂-IIA offers clinical utility as an inflammatory biomarker, specifically in the diagnosis of CVD, the implementation of sPLA₂-IIA is a good starting point for the diagnosis of diseases related to inflammation.⁵ Not only can sPLA₂-IIA be utilized in the diagnosis of CVD, but also in the prevention of secondary coronary events.¹³

REFERENCES

1. World Health Organization. Cardiovascular Diseases. [Online] World Health Organization, May 17, 2017. [Cited: August 21, 2018.] [https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds))
2. WebMD. What is Inflammation? [Online] WebMD. [Cited: January 22, 2019.] <https://www.webmd.com/arthritis/about-inflammation#1>
3. Inflammation and Heart Disease. [Online] Heart.org. [Cited: January 22, 2019.] <https://www.heart.org/en/health-topics/consumer-healthcare/what-is-cardiovascular-disease/inflammation-and-heart-disease>
4. World Health Organization (2018) The top 10 causes of death, <http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death> (Accessed: June 22, 2018).
5. Liu Michael. The need for Group IIA secretory phospholipase A2 (sPLA₂-IIA) inhibitors in inflammatory ocular disease treatment. Medical and Dental Research. 2018; Vol. 1.
6. Kei Yamamoto. Secreted phospholipase A2, lipoprotein hydrolysis, and atherosclerosis: integration with lipidomics. Analytical and Bioanalytical Chemistry. 2011; Vol. 400.
7. Mallat Z, Steg G, Benessiano J. Circulatory secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. Journal of the American College of Cardiology. 2005; Vol. 46.
8. Wilkinson A. Lp-PLA2 (PLAC) Test, Available at: https://tdlpathology.com/media/4932/TAP2268B_PLAC_InformationSheet_V5.pdf. (Accessed: July 3, 2018.)
9. Mallat Z, Lambeau G, Tedgui A. Lipoprotein associated and secreted phospholipases A2 in CD. Circulation. 2010; Vol. 122.
10. O'Donoghue M, Mallat Z, Morrow D. Prognostic Utility of Secretory Phospholipase A2 in Patients with Stable Coronary Artery Disease. Clinical Chemistry; 2011, Vol. 57.
11. Benessiano Joelle. Circulating secreted phospholipase A2 activity: an early prognostic marker in unselected patients presenting to the emergency department with suspected acute coronary syndrome. Science Direct. 2010; Vol. 2.
12. Cook N, Paynter N, Manson J. Clinical utility of lipoprotein associated phospholipase A2 for cardiovascular disease prediction in multi-ethnic cohort of women. NCBI. 2012; Vol. 58.
13. Koenig W. Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with CAD. European Heart Journal. 2009; Vol. 30.
14. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol. 2006; 26: 1586–1593.
15. Liu Ping-Yen. Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention. European Heart Journal. 2003; Vol. 24.
16. NHS. Overview Sepsis. NHS. [Online] NHS. [Cited: December 3, 2018.] <https://www.nhs.uk/conditions/sepsis/>
17. Tan Leong Toh, Goh Yew Yip. The role of group IIA secretory phospholipase A2 (sPLA₂-IIA) as a biomarker for the diagnosis of sepsis and bacterial infection in adults - A systematic review. PLOS ONE, 2017.
18. Mearelli F. Heterogeneous models for an early discrimination between sepsis and non-infective SIRS in medical ward patients: a pilot study. NCBI. 2014; Vol. 9.
19. Truex P, Trias J. Methods for detection and measurement of secretory phospholipase A2 levels (sPLA₂) in biological fluids. Google Patents. [Online] 2007. [Cited: May 1, 2019.]
20. Lamon B, Hajjar P. Inflammation at the Molecular Interface of Atherogenesis: An Anthropological Journey. The American Journal of Pathology, 2008.
21. Venos E, de Koning L. Endocrine markers of diabetes and cardiovascular disease risk. Alberta. Endocrine Biomarkers, 2017.

Rebecca Kirby, serves as a Marketing Executive for **Randox Laboratories**, provider of diagnostic solutions globally.

MONITOR AN INSTRUMENT'S ABILITY TO DETECT PRE-ANALYTICAL INTERFERENCES



There's a certain level of confidence that comes from working with an experienced and knowledgeable QC leader. Feel secure knowing that with our portfolio of products, you'll have access to the resources necessary to build a robust quality control program.

At Bio-Rad, we understand that endogenous interferences are the leading source of errors that clinical labs frequently encounter in the pre-analytical phase of testing¹. That's why we have expanded our portfolio to include Liquichek Serum Indices, used as part of laboratory interference testing to monitor an instrument's ability to detect hemolysis, icterus, and lipemia.

Monitor instrument performance with real-time access to a large interlaboratory program which provides peer group comparisons for benchmarking and troubleshooting.

Learn more about Bio-Rad pre-analytical phase quality indicators:
qcnet.com/serumindices.

¹Plebani M. The detection and prevention of errors in laboratory medicine. Ann Clin Biochem 2010; 47:101-10. <http://dx.doi.org/10.1258/acb.2009.009222>.

Bio-Rad and Liquichek are registered trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.



BIO-RAD

TEST QUESTIONS

Circles must be filled in, or test will not be graded. Shade circles like this: ☒ Not like this: ☐

- The continued rise of cardiovascular disease (CVD) each year represents about _____ percent of all global deaths.
☐ a. five
☐ b. 13
☐ c. 24
☐ d. 31
- What percentage of CVD patients does conventional risk assessment biomarkers detect disease in?
☐ a. five
☐ b. 10
☐ c. 15
☐ d. 20
- The clinical utility of the sPLA₂-IIA test has been proven to be a biomarker for
☐ a. infection.
☐ b. inflammation.
☐ c. toxin exposure.
☐ d. all of the above
- Inflammation has been found to be a direct cause of CVD.
☐ a. True
☐ b. False
- As little as how many risk factors are taken into consideration when determining early risk assessment in individuals?
☐ a. one
☐ b. three
☐ c. five
☐ d. seven
- The sPLA₂-IIA test has been specifically useful in determining the
☐ a. prognosis of current CVD disease.
☐ b. cause of CVD.
☐ c. diagnosis of CVD disease risk.
☐ d. all of the above
- Which family of phospholipase does sPLA₂-IIA belong to?
☐ a. A₂
☐ b. A₁
☐ c. B
☐ d. C
- As well as being an inflammatory marker, sPLA₂-IIA also functions as a
☐ a. herbicide.
☐ b. fungicide.
☐ c. bactericide.
☐ d. all of the above
- The final product(s) produced by the binding of sPLA₂-IIA to phospholipids is/are
☐ a. platelet activating factors (PAFs).
☐ b. leukotrienes and other eicosanoids.
☐ c. prostaglandins.
☐ d. all of the above
- Traditional cardiac markers are used to predict adverse outcomes, whereas the sPLA₂-IIA measurement can be used to predict the inflammatory processes that can potentially lead to a cardiac event.
☐ a. True
☐ b. False
- sPLA₂-IIA modification of lipoproteins has been found to play a direct role in the development of
☐ a. atherosclerosis.
☐ b. arteriosclerosis.
☐ c. pulmonary embolisms.
☐ d. petechiae.
- sPLA₂-IIA acts on the LDL cholesterol membrane to produce small-dense LDL cholesterol particles through a _____ reaction.
☐ a. oxidation
☐ b. hydrolysis
☐ c. enzymatic
☐ d. reduction
- Compared to its less dense form, small particles of which type of lipid has been demonstrated in increasing the risk of coronary heart disease?
☐ a. Lipo-a
☐ b. HDL
☐ c. LDL
☐ d. triglycerides
- Lp-PLA₂ and sPLA₂-IIA both have association with LDL, however sPLA₂-IIA mainly
☐ a. hydrolyses LDL to produce atherogenesis.
☐ b. acts to promote antiatherogenic functions.
☐ c. is carried by LDL to the coronary artery wall and activates inflammation.
☐ d. all of the above
- Research has proven that Lp-PLA₂ has a high association with CVD diagnosis, cardiac death, and MI.
☐ a. True
☐ b. False
- Studies have shown that sPLA₂-IIA has a prognostic value and when percutaneous coronary intervention is used, the sPLA₂-IIA level responds by
☐ a. decreasing immediately.
☐ b. increasing immediately.
☐ c. decreasing about four hours after the procedure.
☐ d. increasing about four hours after the procedure.
- What other disease has sPLA₂-IIA been researched on that shows promising results?
☐ a. sepsis
☐ b. diabetes
☐ c. transient ischemic attack
☐ d. pneumonia
- sPLA₂-IIA has been shown to be a more accurate biomarker than _____ in sepsis patients.
☐ a. CRP
☐ b. WBC count
☐ c. PCT
☐ d. all of the above

Tests can be taken online or by mail. Easy registration and payment options are available through NIU by following the links found at www.mlo-online.com/ce.

PLEASE PRINT CLEARLY

NAME _____

MAILING ADDRESS _____

☐ HOME ☐ WORK

CITY _____ STATE _____ ZIP _____

INSTITUTION/FACILITY _____

PHONE _____

E-MAIL ADDRESS _____

Send your \$20 check payable to Northern Illinois University with this form to: University Outreach Services, Northern Illinois University, DeKalb, IL 60115-2860 Phone: 815-753-0031
 FEE NOT REFUNDABLE OR TRANSFERABLE

P = Poor; E = Excellent

1. To what extent did the article focus on or clarify the objectives?

P ① ② ③ ④ ⑤ E

2. To what extent was the article well-organized and readable?

P ① ② ③ ④ ⑤ E

3. How will you use the CE units?

☐ state license ☐ employment
☐ recertification ☐ other

CE Licensure Information for FL and CA:

FL: Your FL license number: _____ (required for CE credit)

CA: Accrediting Agency: 0001 (for use in submitting your CE credits to CA)

MLO and Northern Illinois University (NIU), DeKalb, IL, are co-sponsors in offering continuing education units (CEUs) for this issue's CE article. CEUs or contact hours are granted by the College of Health and Human Sciences at Northern Illinois University, which has been approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® program. Approval as a provider of continuing education programs has been granted by the state of Florida (Provider No. JP0000496). Continuing education credits awarded for successful completion of this test are acceptable for the ASCP Board of Registry Continuing Competence Recognition Program. Readers who pass the test successfully (scoring 70% or higher) will receive a certificate for 1 contact hour of P.A.C.E.® credit. Participants should allow three to five weeks for receipt of certificate. The fee for this continuing education test is \$20. This test was prepared by Amanda Voelker, MPH, MT(ASCP), MLS, Clinical Education Coordinator, School of HealthStudies, Northern Illinois University, DeKalb, IL.

THANK YOU

TO OUR EDITORIAL ADVISORY BOARD

John Brunstein, PhD, Biochemistry
(Molecular Virology)
President & CSO
PathoID, Inc., British Columbia, Canada

John A. Gerlach, PhD, D(ABHI)
Laboratory Director
Michigan State University, East Lansing, MI

Barbara Strain, MA, SM(ASCP)
Director, Supply Chain Analytics
University of Virginia Health System, Charlottesville, VA

Jeffrey D. Klausner, MD, MPH
Professor of Medicine and Public Health
Division of Infectious Diseases: Global Health, Dept. of
Epidemiology, David Geffen School of Medicine,
Karen and Jonathon Fielding School of Public Health,
University of California Los Angeles, CA

Susan McQuiston, JD, MT(ASCP), SCy(ASCP)
Instructor, Biomedical Laboratory Diagnostics Program
Michigan State University, East Lansing, MI

Donna Beasley, DLM(ASCP)
Director
Huron Healthcare, Chicago, IL

Anthony Kurec, MS, H(ASCP)DLM
Clinical Associate Professor, Emeritus
SUNY Upstate Medical University, Syracuse, NY

Suzanne Butch, MLS(ASCP)^{CM}, SBB^{CM}, DLM^{CM}
Freelance Consultant, Ann Arbor, MI

Paul R. Eden, Jr., MT(ASCP), PhD
Lt. Col., USAF (ret.)
(formerly) Chief, Laboratory Services
88th Diagnostics/Therapeutics Squadron
Wright-Patterson AFB, OH



Chemistry instrumentation—a critical need in Venezuelan labs

By Vanessa Hawrylak, MS, MT(ASCP)

Venezuela's story is a sad one—it went from being the richest country in South America in the 70's and 80's to being one of the world's poorest in 2019. The peace and prosperity that once filled the country has been replaced with violence and extreme suffering. Venezuela is now facing one of the worst humanitarian crises ever to occur in the Western Hemisphere. Nearly 90 percent of the country's



Entrance of oncology clinic

population lives below the poverty level and more than half of the families are unable to meet their most basic needs for food and hygiene.¹ In fact, malnutrition levels are so critical that the Secretary General of the Organization of American States is quoted as saying, "Newborns in Syria have a better chance of survival than those born in Venezuela today."²

While the dictatorial government regime argues that there is not a crisis, the United Nations (UN) and the United States of America (USA) have confirmed the existence of the crisis and the terrible impact it is having on the people of Venezuela. Both the UN and the World Health Organization (WHO) have reported alarming statistics that confirm the magnitude of the problem. According to the *Washington Post*, in 2018, the United Nations Food and Agricultural organization indicated that between 2015 and 2017, 11.7 percent of the Venezuelan population (around 3.7 million), was undernourished. Unofficial statistics indicate that 80 percent of Venezuelans are food insecure with a high percentage of children under five with severe malnutrition surpassing the WHO threshold for crises.²

Building a small STAT lab

As a native of Venezuela, and a healthcare professional in the laboratory field here in the United States, it has become my mission to help those in

need. Utilizing my Venezuelan family and friends as intermediaries, we've identified two organizations that focus on helping children. One organization focuses on providing children with food, education, and comfort while they recuperate from intense malnutrition. The other is an oncology clinic that provides accessible cancer services for pediatric patients. They also provide treatment for patients with leukemia among other blood disorders.

However, the crisis in Venezuela is so critical that these two organizations are struggling to find supplies to help the children. The shortage is so bad in the oncology laboratory that patients may experience a lack of services for up to three months. Currently, the lab can only perform manual hematology tests and they are without a chemistry analyzer. Basic testing is not available, and doctors have been forced to treat patients "blindly." Mortality rates have gone through the roof. The situation is so dire that on many occasions, the medical facilities find themselves without access to electricity or even water. Compounded by the absence of basic sanitation, diseases that were once eradicated long ago are now on the rise—including leprosy, tuberculosis, and typhoid fever. I've been told lab testing has now become a commodity; only those with money can afford to go to a private laboratory for testing.

POCT chemistry equipment need

Thanks to generous contributions and the full support of my employer, Visiun, I have been able to prepare a shipment to facilitate a point-of-care instrument for hematology testing. Soon, I will be able to open a GoFundMe page to help regions that are the most hardly hit. Chemistry analyzers have been the most challenging to find. I've been focusing on locating a (new or used) point-of-care test (POCT)



Infusion area of oncology clinic

SWEET!

A safety lancet whose price won't leave a bad taste in your mouth.



Unistik® Pro

Designed with Comfort Zone Technology® and push-button activation, Unistik® Pro offers a reliable blood sampling solution that is **easy on patients¹ and your wallet.**



Find the Unistik® solution that's right for you.
Contact Clinical Sales at 1-800-421-6936
or email US.info@owenmumford.com

© Owen Mumford Inc. | 1. Data on file. | MLO2019D/OMI/0419/1/US



Laboratory of oncology clinic

or small chemistry analyzer. At minimum, an analyzer can help pediatric oncology patients get basic chemistry tests. My goal is to supply the lab with as many basic needs as possible, focusing on the supercritical patients with the hopes of saving lives.

Through interviews I've learned POCT analyzers are not very common and only a few private laboratories have the ability to support a range of chemistry analyzers—even if the range is just a few. However, a POCT chemistry instrument could be a vital solution to the existing problem. It provides great flexibility for minimizing calibrations and linearities studies that could become costly when using a regular analyzer. It is flexible enough for transportation and support. And most of all, it provides results that can be accurate and reliable for basic testing.

As a medical technologist, I once argued about the reliability of POCT in chemistry testing. However, after experiencing a great deal of instrument training and seeing many technological advancements, I now feel confident enough to say that POCT innovations are demonstrating a great improvement in the medical technology field. In fact, a recent article by Saif Ali Bepari said, "POCT devices in the chemistry industry are considered [important to] support targeted innovations across various disease types." Bepari argues that POCT devices are, "crucial in achieving universal healthcare targets and the usage of POC testing devices is set to increase at higher-tier

health and laboratory settings across developed and emerging economies in the coming years."³

How you can help

As a profound activist of accurate and reliable chemistry test results, I believe that the flexibility of training, transportation, and cost effectiveness of POCT chemistry devices will help resolve major laboratory crises in underdeveloped and crisis-ridden countries such as Venezuela.


Overall, I am very grateful that I work for a company that supports my humanitarian efforts. And most of all I am grateful to family and friends, including my Venezuelan medical technology colleagues, who have put in time and effort to support this cause.

According to many studies, at least 70 percent of medical decisions rely on lab results that give important information on an individual's best course of treatment.⁴ Imagine being a sick, poor child lost in the shuffle of a crisis-ridden country, void of any laboratory testing. Imagine a sick child in the midst of extensive treatment, such as chemotherapy, without any lab tests being performed to monitor their condition. Lab tests are a necessary and fundamental part of a patient's diagnosis and treatment. Due to the current situation in Venezuela, every medical situation has become a guessing game. Will I live? Or will I die?

Should you wish to learn more and/or contribute to my cause of finding medical laboratory equipment and/or supplies for the underserved children of Venezuela, please contact me directly at vanessa.hawrylak@visiun.com or visit one of the organizations directly, Fundacion Kapuy: <https://kapuy.org.ve/>. 📧

REFERENCES

1. Prichard M. Quick facts: Venezuela's humanitarian crisis. Mercy Corps. <https://www.mercycorps.org/articles/venezuela-crisis-quick-facts>. Published April 10, 2019. Accessed April 19, 2019.
2. Broner TT, Page K. Venezuela's health crisis demands an urgent regional response. The Washington Post. https://www.washingtonpost.com/news/global-opinions/wp/2018/11/26/venezuelas-health-crisis-demands-an-urgent-regional-response/?noredirect=on&utm_term=.9b9dcdcc0251. Published November 26, 2018. Accessed April 25, 2019.
3. Saif Ali Bepari. Emerging Trends in Point-of-Care Testing. MedTech Intelligence. https://www.medtechintelligence.com/feature_article/emerging-trends-in-point-of-care-testing/. Published February 22, 2019. Accessed April 26, 2019.
4. Blumer E. 70% of Today's Medical Decisions Depend on Laboratory Results-Lab Professionals Save Lives. bioMérieux Connection. <https://www.biomerieuxconnection.com/2019/04/23/70-of-todays-medical-decisions-depend-on-laboratory-results-lab-professionals-save-lives/>. Published April 23, 2019. Accessed April 26, 2019.



Vanessa Hawrylak, MS, MT(ASCP), serves as Technical Support Specialist at **Visiun, Inc.**, specializing in laboratory compliance and system data analysis. She has a bachelor's degree from UCF Orlando in clinical laboratory science and a Masters of Science in Biomedical Informatics from Nova Southern Eastern University, Fort Lauderdale, FL.



Waiting room of oncology clinic

Infinite Power Together

Consolidate your molecular testing today on a platform that offers scalability and growth for tomorrow.

Visit us at ASM 2019
Booth 527



PANTHER®



**ADD ON
PANTHER FUSION®**



**ADD ON
PANTHER PLUS®**



**ADD ON
PANTHER LINK®**



**ADD ON
PANTHER TRAX®**

WOMEN'S HEALTH AND INFECTIOUS DISEASE ASSAY MENU

CT/NG

Mycoplasma genitalium

Trichomonas vaginalis

Bacterial vaginosis*

Candida vaginitis/

*Trichomonas vaginalis**

HPV

HPV 16 18/45

HSV 1 & 2

Group B Strep

Zika Virus

HIV-1 Quant

HIV-1 Qual Claim**

HCV Quant Dx

HBV Quant

CMV*

Flu A/B/RSV

Paraflu

AdV/hMPV/RV

Bordetella*

GI Panel*

* In development and not for sale as of 5/5/19.

** Seeking dual claim for the HIV-1 Quant assay.

The Aptima Zika Virus assay:

- This test has not been FDA cleared or approved;
- This test has been authorized by FDA under an EUA for use by authorized laboratories;
- This test has been authorized only for the detection of RNA from Zika virus and diagnosis of Zika virus infection, not for any other viruses or pathogens; and
- This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection under section 564(b)(1) of the Act, 21 U.S.C. § 360(b)(3)(b)(1), unless the authorization is terminated or revoked sooner.

ADS-02653-001 Rev. 001 © 2019 Hologic, Inc. All rights reserved. Hologic, Panther, Panther Fusion and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

PANTHER®

PCR: a versatile tool—from detecting genetic diseases and cancers to monitoring stability after bone marrow transplants

By Teresa Snyder-Leiby, PhD

Polymerase chain reaction (PCR) is the foundation for hundreds of molecular DNA tests for the detection and monitoring of a wide range of genetic diseases. Molecular testing methods and examples of the diseases detected include:¹⁻¹²

- Qualitative fluorescence PCR (QF-PCR): Detection of aneuploidy (such as Down syndrome) and repeat expansion diseases (such as Fragile X and Huntington's disease).
- Multiplex Ligation-dependent Probe Amplification (MLPA®) and Methylation Specific (MS-MLPA®) (MRC-Holland reference): Detection of diseases from insertions/deletions/point mutations; including predisposition to cancer (BRCA 1), neuromuscular disorders (Duchenne muscular dystrophy), and aneuploidy.
- Microsatellite instability: Detecting cells deficient in DNA repair capabilities, microsatellite instability-high (MSI-H), or mismatch repair deficient (dMMR) in solid tumors.
- QF-PCR using human identity chemistries is also an essential tool in monitoring engraftment post-transplant.

QF-PCR - aneuploidy

Aneuploidy (an abnormal number of chromosomes) is the most frequent genetic disorder observed in live births and miscarriages, with trisomies being the most prevalent, accounting for approximately 53 percent of all chromosome abnormalities. QF-PCR is quantitative, and the laboratory and data analysis steps can be partially automated for accurate results of more samples in less time than the traditional karyotype method. QF-PCR uses chromosome-specific primers to amplify DNA fragments for each of the chromosomes of interest. DNA fragments are separated with capillary electrophoresis and analyzed by fragment size and number of fragments. The peak height or area, is used to quantify the amount of DNA amplified, determining if the expected pair of each chromosome or aneuploidy is present.

Three DNA fragments—visualized as peaks of approximately the same height in an electropherogram, or peak ratios of 2:1 and 1:2—are indications that the sample is in the trisomic range. Custom chemistries or commercial PCR kits provide primer sets that will detect chromosomes 13, 18, 21, X, and Y. In many cases these multiplexes are sufficient for conclusively detecting and quantifying aneuploidy.

The peak pattern shown in **Figure 1** is an example of a sample that is in the trisomic range for Down syndrome. Peak ratios at loci D21S11 (1:1:1), D21S1437, and IFNAR (1:2) are typical indicators of trisomy 21. Loci D13S634 and D21S1311 contain only single peaks (non-informative). The remaining loci have high heterozygous balance, which is typical of two copies of the homologous chromosomes.

Repeat expansion diseases

Expansions of simple sequence repeats, mainly but not limited to tri-nucleotide repeats, are responsible for over

40 human diseases. In general, an increasing number of repeats results in more severe phenotypes and the number of repeats increase (expand) as the disease gene is inherited. PCR primers are used to amplify the triplet or hexanucleotide repeats. These fragments are separated by capillary electrophoresis. Large repeats are in the high molecular weight range. Molecular weight and number of repeats do not have a strictly linear relationship for larger fragments. Reporting requires a correction for the non-linear relationship. DNA control(s) with fragments of a known number of repeats are included in the PCR and capillary electrophoresis. The size and known number of repeats of the control DNA are used to calculate correction and mobility factors for converting the sample peak size (molecular weight) into a number of repeats.

Figure 2 is a report containing the electropherogram of a Huntington's control sample used to calculate the correction and mobility factors. **Figure 3** is a report of a sample with a single fragment in the normal range and detection of a full expansion of 176 CAG repeats.

MLPA®

Multiplex ligation-dependent probe amplification (MLPA®) is a PCR-based technique developed by MRC-Holland. Since its introduction in 2002, it has become a widely-used and effective technique for detecting copy number variations associated with many common diseases and cancers. MLPA is simpler, more sensitive, and less time intensive when compared to other traditional techniques for detecting copy number variations, including FISH, and Southern blotting.

The MLPA reaction is composed of five steps:


1. DNA denaturation;
2. Hybridization of MLPA probes;
3. Ligation reaction of the two probes hybridized to their target sequence;
4. PCR reaction; and
5. Separation of resulting DNA fragments by capillary electrophoresis. Peak height or area of test samples is compared to control samples with normal copy number for each probe.

Figure 4 is an example of a sample with no duplications or deletions for a spinal muscular atrophy (SMA) test. The red trace in the electropherogram is the normal sample. The blue trace is the test sample. **Figure 5** illustrates heterozygous deletions at the two SMN2 probes, as the test sample peak heights are half the height of the normal sample.

Microsatellite instability

Microsatellites are stretches of DNA where a 1-5 base pair sequence is repeated several times. The most common microsatellite in humans is a dinucleotide repeat of CA which occurs tens of thousands of times across the genome.

How many MSI-H/dMMR solid tumors could your lab be missing by using only IHC-MMR testing?



Learn about the value of performing MSI by PCR and IHC-MMR testing in parallel

www.promega.com/MSIassay



The Promega MSI Analysis System

- Relied on by clinical researchers to characterize the MSI status of solid tumors for 15 years
- Easier to use and less expensive than NGS with a faster turnaround
- Affordable, standardized approach that, when combined with IHC-MMR testing, increase sensitivity and specificity to nearly 100%[†]

120+
peer-reviewed
publications

15
years on
the market

100%
Specificity

Contact our MSI experts to set up a consultation:

PromegaMSI@promega.com

^{*}Dudley et. al (2016) Clin. Cancer Res. 22, 813-820.

[†]Funkhouser et. al (2012) J. Mol. Diag. 14, 91-103; Goodfellow et. al. (2015) J. Clin. Oncol. 33, 4301-8; Bartley et. al (2012) Cancer Prev. Res. 5, 320-7.

Microsatellite instability (MSI) is a key factor in several cancers including colorectal, endometrial, ovarian, and gastric cancers. Colorectal cancer studies have demonstrated two mechanisms for MSI occurrence. The first is in hereditary nonpolyposis colorectal cancer (HNPCC) or Lynch syndrome, where an inherited mutation in a mismatch-repair gene causes a microsatellite repeat replication error to go unfixed. The replication error results in a frameshift mutation that inactivates or alters major tumor suppressor genes. These genes are essential in the regulation of the cell cycle and, ultimately, the prevention of cancer.

The second mechanism whereby MSI causes colorectal cancer is an epigenetic change which silences an essential mismatch-repair gene. In both cases, microsatellite insertions and deletions within tumor suppressor gene coding regions result in uncontrolled cell division and tumor growth. Five markers have been recommended by the National Cancer Institute to screen for MSI in HNPCC tumors (often called Bethesda markers). Generally, MSI detection in two of the markers is considered a positive result or high probability of MSI (MSI-H).

Figure 6 is an example of a sample with MSI-H. The tumor sample fragments are compared to the fragments from non-tumor tissue of the same source by overlaying the electropherograms. The normal tissue is the red trace; the other traces are the tumor sample. Each of the polymorphic loci have additional microsatellite fragments in the tumor sample. The summary table highlights any of the markers with an increase in the number of microsatellite fragments.

Monitoring chimerism

Monitoring post bone marrow transplant chimerism, the extent to which the donor cells have engrafted in the recipient, is essential to confirm stability or detect any signs of graft failure. The analysis uses the same QF-PCR human identity chemistries which amplify short tandem repeats (STRs) used for forensic human identity testing. Highly polymorphic STRs are amplified using a multiplex of STR primers and separated by capillary electrophoresis. Peak heights or areas of fragments from donor and recipient are used to calculate chimerism, the percent of the DNA from the donor.

Figure 7 is an electropherogram from a control 3:1 mixture. Peaks attributed to donor, recipient, or shared are indicated by the flag labels (D, R, D/R). Figure 8 contains the corresponding result table of the percent donor at each locus, total percent donor chimerism, and quality metrics. 

Editor's note: Figures 1-8 and references can be found online at www.mlo-online.com.



Teresa Snyder-Leiby, PhD has served as product manager for DNA fragment analysis software at **SoftGenetics** for 11 years. Teresa was a biology professor at the State University of New York (SUNY New Paltz) prior to joining the support and development team at SoftGenetics.

LSI Medience Corporation PATHFAST® Cardiac Biomarker Analyzer

Improve patient outcomes and hospital efficiencies with PATHFAST.

Troponin

Core Lab quality at point-of-care

The PATHFAST is a compact, fully-automated, bench-top chemiluminescent immunoassay analyzer that provides rapid measurement of cardiac biomarkers from whole blood samples in less than 17 minutes. With the PATHFAST, physicians are able to obtain quality results quickly and accurately, enhancing patient care.

- Core lab quality results in your ED* to help rule out cardiac events faster
- FDA* cleared Troponin I using the 99th percentile with an AHA* guideline acceptable 6% CV*
- Direct measurement from whole blood samples
- 6 parallel channels allows for either 6 samples or 6 tests on one sample to be run simultaneously

* 6%CV at the 99th percentile for Troponin I. Source: IFCC Table of analytical characteristics of commercial cardiac Troponin I and T assay declared by the manufacturer – June 2017 (www.ifcc.org)
Emergency Department, Food and Drug Administration, American Heart Association, Coefficient of Variation

Manufactured By

LSI Medience Corporation.

Distributed Exclusively By



Test Menu

- | | |
|--------------|-------------|
| ■ Troponin I | ■ NTproBNP |
| ■ CK-MB | ■ D-Dimer |
| ■ hsCRP | ■ Myoglobin |

To learn more please visit
www.pathfast.com
800-431-2123
info@polymedco.com

How can something so small be so BIG?

miniMIZE THE HASSLE OF ESR TESTING IN YOUR LAB



Fast, accurate, and reliable results in just 15 seconds
directly from the primary EDTA tube.

ALCORSCIENTIFIC.COM



ALCOR
SCIENTIFIC

Enterprise vs. purpose-built lab RCM systems

Considerations for lab directors

By Lâle White and David Nichols

The laboratory industry has experienced tremendous change in the past few years. New compliance obligations and continued fee compression place an economic burden on many labs. In an attempt to save money, some labs—in particular those associated with hospitals and health systems—are using an enterprise revenue cycle management (RCM) module that is offered as part of the hospital's electronic health record (EHR) software. This article explores what lab leaders need to consider when it comes to the capabilities of enterprise RCM systems vs. those purpose-built for laboratories. The health system may feel the enterprise RCM system is the most cost-effective option, but that fails to take into account the specific needs of the laboratory to maximize its revenue contribution and effectively manage compliance risk.

Compliance

The increasing complexity of compliance obligations for laboratories can seem unsustainable. In the first PAMA (Protecting Access to Medicare Act) data reporting period, few hospital labs were required to report. The definition of applicable lab has been adjusted, so many hospital lab leaders should be collecting the required data and preparing to deliver an accurate dataset during this second reporting period.

Although the definition of applicable lab has been modified, it's still unclear how many hospital labs will be required to report. Nor is it well-understood whether the additional data will have a meaningful impact. It is also unknown whether hospital labs will be able to successfully distinguish outreach data from outpatient data, as is required. According to the American Hospital Association, it is a significant burden on hospitals to effectively distinguish this data and is especially difficult if the lab is using the hospital's enterprise RCM system, as the level of detail required for PAMA reporting is often not collected.

To properly support compliance requirements, labs need RCM and financial management technology that not only helps improve cash collections, but delivers visibility into and control over financial operations. Optimizing billing and accounts receivable processes, intelligently automating workflow, facilitating claim and appeal filing, and removing clerical decision making also reduce regulatory compliance risk.

Payor billing rule changes

The most extensive change to payor billing rules of late is related to the Eliminating Kickbacks in Recovery Act of 2018 (EKRA). The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act) is intended to address the national opioid crisis. EKRA, one of its accompanying

bills, however, has potential impact on many laboratories, including hospitals that provide no services related to substance abuse treatment.

There are things that laboratories can do within their billing and RCM processes to help with EKRA compliance. For example, laboratories need to review policies related to writing off co-pays and deductibles. Under EKRA, it is now a federal felony to write-off these patient responsibility balances as a standard of practice for private payors, as it already is under Medicare. This can be extremely difficult to do with an enterprise RCM, not designed specifically for laboratories.

For example, when a lab offers waivers and discounts, these cannot be fixed amounts, nor have a stated upper limit. It cannot be a one-size-fits-all approach. There needs to be bona fide financial assistance counseling for each patient and attempts need to be made to collect on any balances due. This is especially relevant for hospitals using an enterprise RCM. Because the average in-patient invoice is dramatically higher than the typical outreach lab invoice,

there is a tendency for many hospitals to allocate their collection resources toward the higher value balances, and therefore, smaller lab-based balances tend to be written-off.

A purpose-built lab RCM solution provider, with lab-specific operational expertise, can advise you on mitigating the impact of EKRA by optimizing reimbursements and pursuing a secondary payor strategy to further reduce the patient out-of-pocket. In addition, the purpose-built solution provider can also advise on taking the best

advantage of an organization's data to formulate a strategy for maximizing the organization's "in-network" footprint.

Data visibility

Another impact of running a lab on an enterprise RCM system is that typical enterprise RCM systems do not provide the data visibility required to effectively operate a lab. Purpose-built RCM systems for laboratories use web services to deliver capabilities and information wherever they are needed across the system, including connections with patients and clients through portals as well as interoperating with external systems. The best web services for labs have HIPAA and internet security protocols built in. It is also essential for labs that these two-way data exchanges operate in real time, removing redundancies and data latency.

The information held within lab billing and information systems is useful and powerful. Diagnostic services influence most medical and therapeutic decisions, and the data from the patient's medical record, most relevant for optimizing care, is also diagnostic data. Labs need to leverage these important data assets, but if they are using enterprise RCM systems, they may not be able to fully access, visualize, and thereby benefit from this valuable information.

Failure to report PAMA data accurately can result in severe penalties. Applicable labs that fail to report or report incomplete or incorrect data face potential penalties of up to \$10,000 per day, per line item.

thermo scientific

#MASproductivity

Maximize Quality Control for Your Lab

Thermo Scientific™ MAS™ Quality Controls empower you to optimize your lab's performance when it comes to day-to-day quality control.



30 days
open vial stability*



Ready
to use



3-5 years
shelf life

Find out more at thermofisher.com/MASproductivity

ThermoFisher
SCIENTIFIC

* 30-day open vial stability is available for most MAS Quality Controls.

© 2019 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. Copyrights in and to the image "Leafcutter ant" are owned by a third party and licensed for limited use only to Thermo Fisher Scientific by Getty Images, Inc. All rights reserved.

Data visibility is truly essential, yet just as important are the analytics to help make the data actionable. Analytics help an organization leverage its data assets to understand how the lab is operating, by payor, by specialty, by test, by territory, etc. Analytics also help lab leaders better understand the business they earn from each referring physician. This helps identify opportunities for increasing the value of the relationship. There is also tremendous value to this data beyond the billing department. Clinical data is a treasure trove for analyzing and improving population health.

Business intelligence

Hospital outreach, outpatient, and other diagnostic labs have specific business intelligence (BI) needs that cannot be met by most enterprise RCM systems. Data on the efficiency and effectiveness of lab operations are essential. It is also critical to have fast access to reporting and analytics without impact to production system performance.

Some of the most important BI components and capabilities for labs include:

- Dashboards: view information summaries with ease, and drill down for further detail, if necessary.
- Auditable: ensure data integrity and GAAP/Sarbanes-Oxley compliance. Easily address PAMA and FASB 606 accounting requirements.
- Benchmarking: provide metrics that enable tracking and compare the organization's financial and operational performance to your industry peer group.
- Key performance indicators: use data to understand trends and establish and track key performance indicators.
- Drill-through data: view contextual details related to the data elements by drilling up/down in the summary reports.
- Ad hoc reporting: enable end users to easily build his/her own reports.

Precision medicine

As the healthcare industry continues to adopt precision medicine approaches, labs need informatics technology to integrate clinical, diagnostic, and financial data to enable care teams to gain better insight into the patient's medical situation, make better diagnostic and therapeutic decisions, and improve outcomes. Frankly, this is something that most enterprise RCM systems just cannot do. They are not designed to improve the efficiency of patient care coordination, deliver data visibility or quality metrics reporting for reimbursement, nor to effectively discover actionable insights.

The advancement of precision data creates more complex tests and thus more complex billing. It tends to result in more rejected claims, and thus more appeals. The appeal process can be challenging for labs using an enterprise RCM system, since access to and the attachment of the

data needed for a successful appeal is not automated. This results in manual intervention, which is costly and opens the laboratory up to new risks—including compliance risk.

Lab-specific RCM solutions provide more value

In short, enterprise RCM systems just don't have many of the capabilities required for labs. We see hospital outreach

labs struggling to use the hospital system. From a compliance perspective, in today's environment where new regulatory and payor requirements are being introduced regularly, making a commitment to compliance and obtaining the technology solutions that an organization can rely on to proactively support their compliance needs and programs are imperative. Otherwise the risk is just too great, and it is even harder for hospital outreach labs to succeed.

Too often hospital and health system lab administrators have enterprise RCM systems pushed on them in a misguided attempt to save money. They are told the enterprise system will meet the lab's needs and comes bundled with the cost of the hospital or health system software. Unfortunately, what comes with the enterprise RCM system is the potential for compliance risk, additional labor costs to create the "work-arounds" the lab needs, and sub-par capabilities that fail to maxi-

mize reimbursement for the highly valuable work the lab performs. These labs leave over half their potential profit margin uncollected, because the cost to collect is too high. Only laboratory-specific automation can cost-effectively maximize both AR collections and profitability.

Lab leaders need to rationalize data strategies with business strategies. A lab-specific RCM system can go a long way to making this happen. Value-based pricing is dependent upon the ability to demonstrate financial and economic benefit, which is not possible in an enterprise system. Without leaders focused on technology, data, and strategy alignment, it will be challenging to thrive in today's environment of reimbursement compression and increased regulation. 📌

ADDITIONAL CONSIDERATIONS

Can the RCM system:

- distinguish between billing on order, billing on result, and manage its ramifications?
- identify when the performing location is different than the billing location?
- report collected and expected revenues on a per salesperson basis for commission calculation purposes?
- easily handle bifurcated and multiple fee schedules?
- accurately track and report how much volume is being written-off rather than worked?




Lale White serves as CEO and founder of **XIFN**, a company dedicated to the vision of optimizing the economics of healthcare. A nationally recognized expert in medical financial management and regulatory compliance, with over 35 years of experience in information systems development and medical billing.



David Nichols, MBA, serves as President and founder of **The Nichols Management Group**, leading laboratory consulting for a number of healthcare systems, independent laboratory, biotechnology, private equity, and managed care clients. Nichols has a clinical and anatomic lab consulting practice based in York Harbor, Maine.

100% Complete, Clean Orders from the EHR

Maximize laboratory reimbursements with accurate data in every order



Over 90% of claims denials are preventable. Clean laboratory orders improve the quality of coordinated care, help labs avoid denied claims, maximize reimbursements, and decrease operational costs.

ELLKAY is at the center of the electronic ordering workflow, with a suite of laboratory solutions that deliver end-to-end clean laboratory orders from connectivity to EHRs to data into the LIS, resulting in maximized reimbursements.

ENSURING LABORATORIES RECEIVE THE DATA THEY NEED

- ✓ Updated patient demographics
- ✓ Patient insurance information
- ✓ Insurance eligibility
- ✓ Provider information
- ✓ Rules-based AOE questions
- ✓ ABN checks
- ✓ Diagnosis codes
- ✓ Information related to medical necessity checks and prior-authorization

Diamond-Blackfan anemia: a familial case with emphasis on multi-diagnostic approach to diagnosis and treatment

By Floyd Josephat, EdD, MT(ASCP) and Katrina Goff, MS, MLS(ASCP)

Diamond-Blackfan anemia (DBA) is an autosomal dominant disorder of the bone marrow where an insufficient amount of red blood cells are produced leading to anemia. The condition is named after the pediatricians Louis K. Diamond and Kenneth Blackfan, who described congenital hypoplastic anemia in 1938. This type of anemia usually presents within the first year of life and can lead to a multitude of secondary conditions which will be discussed within this case study.¹ DBA is rare and affects five to seven live births per million worldwide. Corticosteroids is the initial treatment but the Diamond Blackfan Anemia Registry found that 36 percent of those on steroids also require monthly blood transfusions.² This case study will explore a multi-diagnostic approach to testing and treating a familial case of DBA, including hematology, chemistry, and immunohematology. Secondary disorders and diseases such as myelodysplastic syndrome, hemochromatosis, and organ failure will be discussed, as well as gene therapy, bone marrow transplants, and leucine therapy treatments.

Anemia

According to the National Heart, Lung and Blood Institute (2012), anemia is any condition leading to a shortage of red blood cells.³ There are different types of anemia, some not life threatening and some that are very serious. DBA is a type of serious anemia that is chronic and has a strong genetic component. DBA is a failure of the bone marrow to produce an adequate supply of red blood cells. This shortage causes the anemic state in patients and leads to an overall depletion of oxygen throughout the body.⁴ There are some physical abnormalities that are sometimes associated with this disorder but will not be discussed here, since the patients involved did not demonstrate any such abnormality. Several mutations of ribosomal proteins have been found in those suffering from DBA with 25 percent showing a mutation on the RPS19 gene. This was surprising since the mutation was thought to be due to a deregulation in erythropoiesis.⁶ This disorder is also autosomal dominant which means that only one copy of the gene is needed to cause the disease.⁴

Diagnostic criteria

Diagnostic criteria for DBA from the 2008 International Clinical Care Consensus Document are: age less than one year, macrocytic anemia with no other cytopenias, reticulocytopenia, normal bone marrow cellularity with a decrease in red cell precursors, and normal platelet and neutrophil counts.^{7,2} Treatment options for those suffering from DBA initially start with corticosteroid treatment. A large dose is given for the first two weeks after diagnosis to initiate the bone marrow to produce more red blood cells though the mechanism behind this is unknown. After the initial dose, a sustainable dose is given and the possible adverse

side effects that come with steroid use are monitored (upset stomach, increased blood sugar, increased blood pressure, and increased risk for infection). The Diamond Blackfan Anemia Registry found that 82 percent were initially responsive to steroids. Thirty-six percent of that 82 percent also received monthly blood transfusions.²

Most patients suffering from DBA have to receive blood transfusions every three to six weeks. The patients hemoglobin is monitored (usually monthly) to ensure it is not dropping to a dangerous level. People with DBA usually have scheduled transfusions to ensure this doesn't happen. These patients sometimes present a problem for the healthcare worker since getting good access to a vein may be difficult in someone who receives chronic transfusions. It is also a challenge for the patient to receive appropriate blood when they begin developing antibodies to prior blood that they have received. Chronic transfusions are also dangerous since they increase the risk of a transfusion reaction. Those who are transfusion dependent are also at an increased risk of developing a disorder called hemochromatosis, which is essentially iron overload.²

Hemochromatosis is monitored by ferritin levels which indicate the levels of iron in the body. If iron overload is found to be an issue, chelation therapy can be done to remove the excess iron. There are currently two chelation drugs approved by the FDA: Exjade and Desferal. Exjade is an oral drug that binds the iron and removes it through the stool. Desferal is an injectable treatment over eight hours that removes the excess iron through urine.² Stem cell, or bone marrow transplants are also a possible treatment for those suffering from DBA. If successful, the bone marrow then functions normally and makes an adequate amount of red blood cells. The risks for a bone marrow transplant are numerous, including death if a rejection occurs.²

Laboratory diagnosis

Hematology

Numerous tests performed in the hematology department are vital in a doctor's treatment of a DBA patient. Those who are transfusion dependent have a CBC done every three to six weeks, usually coinciding with their transfusion protocol. Those on steroid therapy need fewer CBC's, mainly to check for infections due to lowered immune response. Elevated adenosine deaminase is an enzyme that breaks reticulocytosis. When thrombocytopenia is seen, a bone marrow aspirate is usually performed to check for bone marrow failure or the development of myelodysplastic syndrome or aplastic anemia.⁵

Macrocytosis (red blood cells that are larger than normal) is often seen with DBA. A study done by Pesciotta et al researched whether the macrocytosis was due to protein translation malfunctions by looking at the proteomes in patients with DBA versus samples from healthy patients.



When it comes to
serum free light chain testing,

FREELITE ON OPTILITE IS THE ULTIMATE SOLUTION

► Only Freelite serum free light chain assays are FDA cleared for both diagnosis and monitoring of Multiple Myeloma and AL Amyloidosis

► Only Freelite is referenced in >3,000 publications, the result of >18 years of clinical utility

Ensure the best possible performance

Both the assays and the analyzer are optimized by Binding Site

Capture very high Myeloma samples without manual intervention

Optilite automatically re-dilutes to end result

Use less reagent

Assays are designed with wide measuring ranges and large dilution steps

Visit Binding Site Site **Booth #1927** at AACC 2019.

Optilite and Freelite are registered trademarks of The Binding Site Group Ltd (Birmingham, UK) in certain countries.

Contact us to learn more.

Binding Site Inc.
Tel: 800-633-4484

info@bindingsite.com
www.bindingsite.com

Protein diagnostics.
Smart solutions.



**Binding
Site**

Most DBA patients also have an increase in fetal Hgb, a decrease in adenosine deaminase activity, and reticulocytosis. Ribosomal protein S19 accounts for up to 25 percent of the 11 proteins that undergo mutations in DBA. Of the four DBA patients who underwent proteomic analysis, abnormal proteins were found in all four including dysferlin and MHC class 1 proteins. Findings suggest that DBA protein mutations on RBC's are special unto themselves.⁷

Incidence of cancer in DBA is highly elevated, more specifically acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS). Clinical presentations and therapies vary greatly between individuals. Vlachos, Atsidatos, Alter, and Lipton did a retrospective study where they took 608 individuals from the DBA registry in North America and measured incidence of MDS and AML. Of the 608 total patients studied, 17 patients with DBA had more than one type of cancer with 15 demonstrating solid tumors and two with AML. Four patients developed MDS. Eight patients were transfusion dependent at the time of cancer diagnosis, two were in remission, and four had never been treated for anemia. Of the 18 who had cancer, ten had a mutation in a ribosomal protein gene known to be associated with DBA. Three of the four most common genotypes were represented: five with RPS19; two with RPL11 (mother and daughter); and two with RPL5. The median overall survival for all patients was 56 years.⁸

Immunohematology and chemistry

Iron is an important metal within the body responsible for DNA synthesis as well as oxygen binding. There is no method for ridding excess iron naturally so iron overload can be problematic in those receiving multiple transfusions. One unit of red cells has 200 mg of iron, which is more than double the daily recommended dose.¹⁰ Ferritin is often used as an indicator for overall iron storage in the body. Generally, ferritin levels are therapeutic in DBA patients at levels between 1,000 and 1,500 ng/mL. These levels are measured every three months and if instability is seen, an MRI is usually ordered to rule out liver and/or tissue damage.⁵ Liver and cardiac damage is not uncommon in those receiving multiple transfusions since the excess iron leads to deposits (called hemosiderins) accumulating in liver and cardiac tissue.⁹ Shander, Cappellini, and Goodnough reported on a retrospective study in 2009 that studied 152 patients who had a total of 4,875 units of red cells transfused from 1987-1998. The study found that those who demonstrated iron overload had a much higher organ failure and mortality rate than those who did not show elevated ferritin.¹⁰

Treatment

Leucine is an amino acid that aids in protein synthesis regulation and is a possible future treatment for those suffering from transfusion dependent DBA. Jaako et al in 2012 looked at the effects of leucine in a mouse model who was RPS-19 deficient. Double the amount of leucine found in serum was given in drinking water to the mice. The study concluded that of those given the leucine there was a significant increase in red blood cells as well as hemoglobin concentrations. There appeared to be no adverse side effects.¹¹ This has huge implications for those with DBA since the disease carries with it so many adverse secondary complications.

CBC		REFERENCE RANGES
WBC	3.1	4.5-11.0 thou/ul
RBC	3.5	4.5-5.9 mill/ul
HGB	10.1	13.5-17.5 gm/dl
HCT	28.6	41.0-53.0 %
MCV	82.7	80-95 fl
MCH	29.1	25-35 pg
MCHC	35.2	25.0-35.0 gm/dl
RDW	18.6	11.5-14.5 %
PLT	300	150-450 thou/ul
NEUT	54	40-70 %
LYMPH	32	15-45 %
MONO	10	1-8 %
EO	3	0-6 %
BASO	0	0-2 %
MORPH	MOD ANISO	
PT	15.4	11.8-15.2 sec
INR	1.18	0.00-1.49
PTT	40.9	22.1-35.7 sec
CHEM		REFERENCE RANGES
GLU	116	75-110 mg/dl
Na	137	137-145 mmol/L
K	4.1	3.6-5.0 mmol/L
Cl	104	101-111 mmol/L
CO2	29	21-31 mmol/L
ANION GAP	8.1	7.0-14.0
BUN	12	9.0-21.0 mg/dl
CREA	0.8	0.40-1.30 mg/dl
Ca	8.7	8.5-10.5 mg/dl
TP	6.4	6.0-8.4 gm/dl
ALB	3.7	3.0-5.0 gm/dl
A/G RATIO	1.4	1.0-2.2 gm/dl
GLOBULIN	2.7	1.5-3.8 gm/dl
TBILI	1.2	0.2-1.3 mg/dl
AST	41	5-49 IU/L
ALK	92	38-126 IU/L
ALT	65	7-56 IU/L
LACTIC ACID	13.5	6.5-19.3 mg/dl

Table 1: Patient's CBC profile and coagulation parameters
Lab values: Father



The Intelligent Analyzer.

Introducing GEM Premier 5000 with iQM2—for improved patient care.

New GEM Premier 5000 blood gas testing system provides automated quality assurance with every whole-blood* sample. Now with next-generation Intelligent Quality Management (iQM2), featuring *new* IntraSpect™ technology, potential errors are detected not only before and after, but also *during* sample analysis, along with real-time correction and documentation. Plus, it's simple—just change the all-in-one GEM PAK once a month. So regardless of testing location or point-of-care operator, quality results and compliance are assured with every sample.

Real-time assurance and advanced simplicity. Now that's intelligent.

For more information in North America, call 1.800.955.9525 or visit instrumentationlaboratory.com
Outside North America, visit werfen.com

*Heparinized.



510(k)-cleared. Health Canada-licensed. Not available in all countries.
©2018 Instrumentation Laboratory. All rights reserved.

CBC	PRE-TRANSFUSION	POST-TRANSFUSION	REFERENCE
WBC	2.9	2.3	5-14.5 thou/ul
RBC	3	3.8	4-5.2 mili/ul
HGB	8.2	11.1	11.5-15 g/dl
HCT	24.5	32.1	35-45 %
MCV	82.4	84.7	77-95 fl
MCH	27.7	29.4	25-33 pg
MCHC	33.6	34.7	31-37 g/dl
RDW	16.5	15.5	11.5-14 %
PLT	259	303	150-450 thou/ul
NEUT	33	26	34-56 %
LYMPH	49	55	24-54 %
MONO	11	11	3-10 %
EO	6	7	0-5 %
BASO	1	1	0-2 %
FERRITIN		REFERENCE	
14-Aug	2484	23.9-336.2	
27-Jun	2109		
25-Apr	2712		
6-Jan	2180		
19-Nov	1677		
24-Oct	2238		
14-Aug	1907		

Table 2: Patient's CBC profile and coagulation parameters
Lab values: Son

Case study presentation

A 29-year-old man presented to the ER with complaints of fever, chills and coughing. His initial exam showed a temperature of 101.1 and a pulse oximetry of 94 percent. During the course of taking the patients history, it was noted that he has DBA and has had iron overload. His current medications included Exjade taken by mouth daily. A PT, PTT/INR, CMP, CBC were ordered, and Ibuprofen was given for the fever. His CBC results showed low WBC, RBC, HGB, HCT, and lymphocyte levels with elevated RDW and neutrophils. His CMP showed high glucose and ALT. (Table 1) His immunohematology records were checked and the patient received a full antigen typing of his red cells, and has since been transfused monthly.

This patient also has two sons, one six and the other five years of age. Both inherited DBA. Their records indicate that they get labs drawn and transfusions on a bi-monthly basis. The oldest son's labs consistently show low RBC, HGB, HCT, and reticulocyte levels with extremely high ferritin levels. (Table 2) Both children

have now started to show signs of autism, but no correlation has been made with autism spectrum disorder and DBA. The children are responding well to the transfusions and no plans have been made for bone marrow transplants.

Conclusion

DBA is a disease of the bone marrow that causes insufficient red cell production. This case study was about a family that suffers from DBA. The case study was developed to provide an overview of the disease with emphasis on a multi-diagnostic approach to help diagnose and treat this disease. DBA presents differently in every person affected and has a variety of treatments. Unfortunately, all of those treatments as well as the disease itself carries many secondary risks. ➔

REFERENCES

1. <http://www.cdc.gov/ncbddd/dba/facts.html>. Published 2019. Accessed May 3, 2019.
2. DBAR Findings | Diamond Blackfan Anemia Foundation, Inc. <http://dbaafoundation.org/learn-more/dbar-findings/>. Published 2019. Accessed May 3, 2019.
3. Anemia | National Heart, Lung, and Blood Institute (NHLBI). <http://www.nhlbi.nih.gov/health/health-topics/topics/anemia/>. Published 2019. Accessed May 3, 2019.
4. Reference G. Diamond-Blackfan anemia. Genetics Home Reference. <http://www.ghr.nlm.nih.gov/condition/diamond-blackfan-anemia>. Published 2019. Accessed May 3, 2019.
5. Vlachos A, Muir E. (2010). How I treat Diamond-Blackfan anemia. *Blood*, 116(19), 3715-3723. doi:10.1182/blood-2010-02-251090/.
6. Flygare J, Karlsson S. (2007). Diamond-Blackfan anemia: erythropoiesis lost in translation. *Blood*, 109(8), 3152-3154.
7. Pesciotta EN, Sriswasdi S, Tang H, Speicher DW, Mason PJ, Bessler M. (2014). Dysferlin and other non-red cell proteins accumulate in the red cell membrane of diamond-blackfan anemia patients. *PLoS One*, 9(1), e85504. doi:<http://dx.doi.org/10.1371/journal.pone.0085504>.
8. Vlachos A, Rosenberg P, Atsidaftos E, Alter B, Lipton J. (2012). Incidence of neoplasia in Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry. *Blood*, 119(16), 3815-3819. doi:10.1182/blood-2011-08-375972.
9. Stumpf J. (2007). Deferasirox. *American Journal of Health-System Pharmacy: AJHP: Official Journal Of The American Society Of Health-System Pharmacists*, 64(6), 606-616.
10. Shander A, Cappellini MD, Goodnough LT. (2009). Iron overload and toxicity: the hidden risk of multiple blood transfusions. *Vox Sanguinis*, 97(3), 185-197. doi:10.1111/j.1423-0410.2009.01207.
11. Jaako P, Debnath S, Olsson K, Bryder D, Flygare J, Karlsson S. (2012). Dietary L-leucine improves the anemia in a mouse model for Diamond-Blackfan anemia. *Blood*, 120(11), 2225-2228. doi:10.1182/blood-2012-05-431437.



Floyd Josephat, EdD, MT(ASCP) serves as Associate Professor of Hematology and Program Director of the Clinical Laboratory Science and Clinical Pathologist Assistant Programs at the University of Alabama, Birmingham. Josephat has been a clinical laboratory scientist for over 27 years and is board certified by the American Society for Clinical Pathologists (ASCP).



Katrina Goff, MS, MLS(ASCP), has been a Medical Laboratory Scientist for five years and currently works in the hematology department at the Columbia VA Health Care System in Columbia, SC.

K-ASSAY® . . . *High-Quality, Low-Cost Reagents*

Immunoassay Reagents for chemistry analyzers™

Over 37 different assays available

Nutrition

Ferritin
Prealbumin
Retinol Binding Protein
Transferrin

Serum Proteins

α -1 Acid Glycoprotein
 α -1 Anti-Trypsin
 α -1 Microglobulin
 β -2 Microglobulin
Haptoglobin
IgA
IgG
IgM

Allergy
Total IgE

Stomach
*H. pylori**

Diabetes

Cystatin C
Hemoglobin A1c
Insulin
Microalbumin
Microtransferrin*

Inflammation / Cardiac

Anti-Streptolysin O
Complement C3
Complement C4
CRP
Rheumatoid Factor

Coagulation

D-Dimer
Fibrinogen
Factor XIII
Plasma FDP*
Serum/Urine FDP*

Lung

KL-6*

Lipid Assessment

Apo AI
Apo AII*
Apo B
Apo CII*
Apo CIII*
Apo E*
Lp(a)
Remnant Lipoprotein
Cholesterol*

New Products Now Available!!

- β -2 Microglobulin reagent for chemistry analyzers
- *H. pylori* Test Reagent* for chemistry analyzers
- KL-6 (Krebs von den Lungen-6)* reagent for chemistry analyzers
- Microtransferrin* reagent for chemistry analyzers
- Remnant Lipoprotein Cholesterol* reagent for chemistry analyzers
- Retinol Binding Protein reagent for chemistry analyzers

* Research Use Only

KAMIYA BIOMEDICAL COMPANY
www.k-assay.com/MLO.php

diagnostics@k-assay.com | 800-KAMIYA-5

Quantitative trait loci—uncovering genes for continuously variable traits

By John Brunstein, PhD

In this month's episode, we're going to take a bit of a detour out of front-line molecular testing methods and delve a bit into something more theoretical but with impacts on molecular testing. It's likely something you haven't encountered unless you have a specialized genetics background, and it's also something readers of this column may have wondered about in some form and may find of interest.

Mendelian isn't everything: QTLs

Let's start by considering something even the non-genetics specialists have some familiarity with—that is, simple Mendelian genetic traits. These are phenotypic (physical appearance or behavioral) traits which can be classified in discrete and mutually exclusive bins, like eye color. You might have green, blue, or brown eyes, but each of these is readily distinguishable—it's not like there is a continuous rainbow spectrum of natural human eye colors. Other examples of discrete Mendelian traits in humans would be hairy pinna (earlobes) or widow's peak (hairline). There are many more possible examples of less visibly obvious traits such as enzyme isoforms with discrete Mendelian states having biochemically measurably different behavior. However, for a great many phenotypic traits we actually have a continuous spectrum of outcomes rather than discrete states. Think for example height, or longevity, or resting blood pressure. In fact, a great many of the phenotypic behaviors we'd like to know more about express themselves in this quantitative—as opposed to quantized—form. An example, which probably nobody cares about but which serves illustrative purpose might be, "rate of fingernail growth."

The immediate complexity which springs to mind when we consider these types of measurements is that the end result observed in each individual is based both on genotypic and environmental factors, or "nature and nurture" as it's sometimes called. A second level of complexity arises when we consider that these sorts of traits are likely to be influenced to a larger or smaller degree by multiple genes working in combination (a polygenic trait). Additional confounding issues could also possibly be epigenetic modifications to genes through mechanisms such as base methylation or histone acetylation influencing expression levels, or finally "variable penetrance" which is something of a catch-all term applied in genetics to cases where although a particular allele of a gene has a known effect, the scale of that effect is variable for reasons we don't have a firm grasp on. What we'll discuss in this month's article is "QTL (Quantitative Trait Loci) mapping," the approach taken to help identify genes and their alleles influencing quantitative loci of

interest, with strategies to deal with our first and second confounding issues (and quite possibly our fourth issue). Epigenetic modification is a bigger topic and one we'll leave out of the mix for now.

Step 1: Genetic markers and association statistics

Our first step in this puzzle is to have a relatively high density of randomly distributed genetic markers across the genome. These can take the form of any sort of identifiable "tag" which allows us to track its closely physically associated (linked) DNA. Single Nucleotide Polymorphisms (SNPs) are one of the most common type of such tag—single nucleotides at known locations in the genome, which exists in more than one form in the population. We might for instance note one location which is "A" in 70 percent of genomes making up our population and "C" in the remaining 30 percent. It doesn't matter whether this is in a coding region or not (statistically, it probably isn't) or whether the two alleles have any actual physical significance (even more unlikely)—all we care about is we now have a differentiable physical spot in the genome. As genetic recombination is a stochastic process, DNA sections near this marker stay attached to it more frequently than DNA sections further removed. If we have enough of these markers then we can track the movement of fairly small sections of DNA as they reassort through recombination and sexual reproduction to create individual genomes.

With these densely and randomly scattered markers on hand, we can now take sample individuals from our population and essentially do nothing more than look for statistical association of particular marker(s) with our trait of interest—in this case, rate of fingernail growth. We're looking for one or more sections of DNA, whose inheritance seems to track with a measure of our phenotype, such that we can make statements like "With regard to this SNP, we observe faster fingernail growth in 97 percent of 'C:C' genotype individuals as compared to 'A:A' genotype individuals." What we are actually observing is that there is some gene near to our marker, and at some time in the past on a chromosome which carried the allelic form of that gene which contributes to faster fingernail growth, there was a mutation at the nearby SNP transverting an A to C residue. (The temporal reverse is also possible, such that A and C SNP alleles came into existence and then the gene near one of these mutated. The result is the same, a functional gene allele is linked to a detectable marker.) Because these are physically closely linked, recombination between the marker and the allele of interest is rare and the marker now moves around as a surrogate for that allelic variant. Note that 'rare' doesn't mean 'never,'

Sepsis? Septic Shock?

Measure Lactate *Bedside*

New Study Shows Early Lactate Measurement Improves Outcomes for Sepsis

Sepsis remains a leading cause of morbidity and mortality. Because of a strong association between elevated lactate levels and increased mortality, sepsis guidelines call for lactate testing soon after the onset of sepsis. The U.S. Centers for Medicare and Medicaid Services Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) mandates an initial lactate be drawn between 6 hours before and 3 hours after severe sepsis presentation.

- In a new study of 5,762 patients that met SEP-1 criteria for sepsis, only about 60% of patients had an initial lactate drawn within the SEP-1 window.¹
- Each hour of delay in initial lactate measurement was associated with delayed antibiotics and an increase in mortality.¹
- “Systematic early lactate measurement when a patient presents with sepsis may thus be useful in prompting earlier, potentially life-saving interventions.”¹

Fast, Easy Bedside Testing

StatStrip Lactate is a hand-held, true point-of-care system that brings lactate testing directly to the patient's bedside. Lactate is currently measured on blood gas analyzers, which creates numerous problems for bedside testing. Blood gas analyzers are typically in a fixed location. They require large samples (as much as 700 microliters) and sample labeling and transport. They have analysis times as long as 3 minutes, and are expensive to purchase and run.

As easy as bedside glucose testing, StatStrip Lactate uses a disposable biosensor to provide the fastest turnaround time (13 seconds) on the smallest whole blood sample (0.6 µl) with lab-like accuracy.



¹Marra A et al. Implications of Centers for Medicare & Medicaid Services Severe Sepsis and Septic Shock Early Management Bundle and Initial Lactate Measurement on the Management of Sepsis. *Chest* 2018;54(2):302-308.



and a first statistical value we get is strength of association (here, 97 percent) which also is a surrogate measure of what the actual distance is between the marker and the gene. If we're particularly lucky we may even have two or more genetic markers which demonstrate this sort of linkage association and based on their relative frequencies of association, we can narrow down the general area of DNA the gene likely resides in based on relative closeness to these markers. Luck in this case is greatly increased as marker density increases, of course—high density marker maps make the entire QTL mapping process easier than lower density maps.

More statistics: effect sizes

There is an unrelated second statistic we should look for with our now-linked marker, and that is effect size. Imagine for instance when we looked for markers associated with fingernail growth rate, we found three widely separated markers with statistical relevance. All have one allele which clearly shows accelerated fingernail growth rate, but compared to some baseline reference value, Marker A shows a three percent increase in growth rate, Marker B shows a 22 percent increase, and Marker C shows a seven percent increase. (Strictly speaking the statistics would be more complicated than that, such as having a 95 percent confidence interval range of effect, but we're ignoring these nuances here because they can—and do—fill entire textbooks. There are even multiple completely different statistical approaches to identifying our linked markers. For the sake of brevity, we're avoiding all of that as the basic concepts as presented here remain valid across all these approaches.) These values suggest the relative scale of impact each gene has on the final phenotype.

And the candidate gene is...

Now armed with the knowledge of what regions have the biggest impact on fingernail growth rates, we can proceed (probably from the biggest impact markers to lowest) to look for likely candidate genes. If we find an ORF (open reading frame, a potential protein coding region) near one of our markers, and we find its translated amino acid sequence for example has a high degree of similarity to a known keratin synthase gene, that would make sense and be a good candidate. Our evidence for its involvement would get even stronger if we find this gene expressed as an RNA (or even just a fragment of it, in parlance an EST, Expressed Sequence Tag) telling us that it's an active gene. If we could then find either amino acid variations in this candidate gene, or variances in its RNA expression level, which correlate with our phenotypic observations of fingernail growth rate, we can become increasingly certain that we've found our actual gene contributing to the continuous phenotype. A full proof would then best be done by targeted gene modification in whatever our model organism is for fingernail growth (the genetic equivalent of fulfilling Koch's Postulate, by making the genetic change in an otherwise controlled background and environment and observing the expected effect). If there is no well established model system, then at least cloning

of the variant gene forms, in-vitro protein expression, and enzyme kinetics studies can be nearly as helpful by demonstrating that yes, the protein version as coded for by gene found associated to the "C" SNP has faster enzymatic behavior than the version found associated with the "A" SNP. Follow these approaches through on the other identified linked loci and candidate genes to rule them in or out, and we have now fulfilled our lab's lifelong academic ambition of understanding multiple genes influencing fingernail growth rate.

Resolving complexities

We mentioned above that this approach would attempt to address the challenge of "nature versus nurture." Part of this is through the effect size values discussed above; generally, if the genetic effect is big enough, "nature" is more important than "nurture" and an effect is visible even with disparate environmental factors. Other approaches however can include things like linking in family pedigree information, where sibling studies can be done on the hopes that environments will be similar; things like dizygotic twins can be particularly useful here. Alternatively, if there are suspected particular environmental factors, these may be accounted for in collected and paired metadata for each genetic subject. The second complexity—polygenic traits—was directly dealt with above, as we were able to identify multiple loci. The fourth complexity—our fudge factor of "variable penetrance"—to some extent may be explained away once we have our data in hand, as we start to show that all of loci A, B, and C are involved but we don't see all of the impact of a particular allele at A unless we also have a particular allele at C. This is no longer variable penetrance, it's a definable epistatic gene interaction. Finally, although we said we'd ignore the third complexity of epigenetics, it's becoming increasingly possible from a laboratory technical perspective to capture data on things like DNA methylation during sequencing. Analogous statistical approaches to identify differential patterns of epigenetic labeling of particular gene regions correlating to phenotype are of course possible and will likely become more commonplace as the underlying data becomes more commonly available.

Having complete genomes of organisms in orders of magnitude is cheaper and easier than it was only a few years ago. Making sense of all of that information, by understanding how these genes contribute not just to discrete Mendelian traits but to all the complex polygenic continuously variable metrics we can imagine, is the next step in making good use of the data. Hopefully, the forgoing has demystified the process for those of you not already familiar with it. Should it merely have wet your appetite for the subject, there are numerous good up to date texts on the subject available. 🍷



John Brunstein, PhD, serves as an Editorial Advisory Board member for MLO. John is also President and CEO for British Columbia-based **PathoID, Inc.**, which provides consulting for development and validation of molecular assays.

IT'S COMING...

CLR[©]

CLINICAL LABORATORY REFERENCE

FEATURING OVER 4,900

tests

equipment

products

services

+

REFERENCE GUIDES

drug levels

toxicity levels

critical values

reference intervals

OPENING AUGUST 2019

(alongside MLO)

RESERVATIONS: MLO-online.com/subscribe

ESR analyzer



miniSED is the newest addition to the iSED family of Erythrocyte Sedimentation Rate (ESR) analyzers from ALCOR Scientific. The miniSED measurement of ESR is fast, accurate, and unaffected by variables associated with traditional methodologies, such as hematocrit. This single position, fully automated ESR analyzer works

directly from primary EDTA tubes or BD Microtainer MAP Microtubes, requires 100 microliters of sample, has an internal barcode reader, and produces results in 15 seconds. The miniSEDs small footprint combined with its advanced design and rapid time to result benefits ESR testing for small laboratories, POL's, and emergency clinics. Manufactured in the USA. **ALCOR Scientific, www.rsleads.com/906ml-150**

Hematology analyzer



The DxH 900 hematology analyzer enables clinical laboratories to perform complete blood count and white blood cell differential tests with minimal repeats. Demonstrating a 93 percent first-pass throughput, DxH 900 provides users with RBC, PLT, and WBC differentials through near native-state cellular characterization. This helps to generate reportable results as quickly as possible, reducing the time, supplies, and costs that may be required for systems with higher repeat rates. DxH 900 users can also

utilize the Early Sepsis Indicator; a new hematologic biomarker designed to help emergency department physicians identify patients with sepsis or at increased risk of developing sepsis. **Beckman Coulter, www.rsleads.com/906ml-151**

Blood group genotyping analyzer



Grifols blood group genotyping analyzer for when pre-transfusion testing requires (a) challenging antibody identification, i.e. warm autos, anti-CD38/CD47 patients, high-frequency antigen, no

antisera available, recently transfused; (b) avoidance of generating antibodies that could harm future transfusion outcomes (regularly transfused patients, i.e. Sickle Cell, SCIDs, beta-Thalassemia, cancer); (c) shortened testing time for challenging antibody workups; (d) saving costs in laboratory testing, frequency of transfusions, and hospital bed stay; (e) saving in future testing costs as the genotype never changes (except for in bone marrow transplants); (f) bypassing common limitations in serology; (g) matching blood unit to patient at the genotype level to account for more blood group variability; and (h) improving transfusion outcomes for patients in need.

Grifols, www.rsleads.com/906ml-152

Molecular testing

Panther Scalable Solutions allows you to consolidate your molecular testing on a platform that offers scalability and growth. The Panther system is the foundation, with the option to add on: Panther Fusion, Panther Plus,* Panther Link,* and Panther Trax.* Choose from a selection of 14 available assays and six more in development. Panther Scalable Solutions expands your testing menu while adding on flexibility, capacity, and walkaway time.*In development and not for sale. **Hologic, www.rsleads.com/906ml-153**



High-volume chemistry analyzer

The CLC1600 is a high-volume chemistry analyzer for both mid- and large-size clinical labs. It offers up-to-date software, micro-electronics, fluidics, and hardware. It accommodates up to four-part reagents, bar-coded sample tubes, and features discrete, random access, batch, and stat capabilities. The CLC1600 features up to 900 photometric tests per hour (1200 with ISE), uses less reagent, requires less maintenance, and is matched with customer support and service. **Carolina Liquid Chemistries, www.rsleads.com/906ml-154**



Free light chain and special protein testing

Freelite on Optilite is a solution for free light chain and special protein testing. The Optilite, with its method of antigen excess protection and auto dilution to end results enables results to be delivered efficiently and accurately. Freelite is FDA cleared for monitoring of myeloma and AL amyloidosis, has been mentioned in international guidelines, and is referenced in over 3,000 scientific publications. **Binding Site, www.rsleads.com/906ml-155**



Fully automated random access bench-top systems

Thermo Scientific Indiko series, Indiko and Indiko Plus, are fully automated random access bench-top systems for clinical and specialty chemistry testing. Analyzer, reagents, and consumables form a fully supported system solution offering to the laboratory ease of use and time saving automation that supports routine daily work. The Indiko systems are targeted to small and medium sized laboratories. **Thermo Fisher Scientific, www.rsleads.com/906ml-156**



Save More Lives.

by screening for colorectal cancer.

OC-Auto[®] *80* MICRO

**Automated FIT
(Fecal Immunochemical Test)**

- Only FDA cleared automated FIT
- Recommended FIT by the USPSTF - "The OC-Light and the OC FIT-CHEK (OC-Auto) family of FITs (Polymedco, Inc., Cortlandt Manor, NY) have the best test performance characteristics (i.e., highest sensitivity and specificity)."¹
- 1 patient sample
- Completely closed sampling bottle
- Convenient patient take home packs and absence of dietary restrictions for maximum patient compliance

epi pro colon[®] 


**Blood Test for Colorectal
Cancer Screening**

- FDA Approved for colorectal cancer screening for people who are unwilling or unable to be screened by recommended methods.
- Epi proColon is a molecular test that detects methylated Septin 9 DNA in blood.
- DNA methylation of the SEPT9 gene is increased in colorectal cancer.
- Methylated Septin 9 DNA can be found in tumor DNA that has been shed into the bloodstream from proximal and distal colon and rectal sites, making it a differential biomarker for the early detection of colorectal cancer.

"Increasing screening rates to 80% by 2018 would prevent 277,000 new cases of colon cancer and 203,000 deaths within 20 years."²



Clinical chemistry analyzer




The RX imola is a cost-effective clinical chemistry analyzer. With a throughput of 400 photometric tests and up to 560 tests per hour including ISE, the RX imola provides rapid, comprehensive testing on a small footprint, bench-top analyzer. Random access, STAT sampling, and intuitive software

functionality enable boosted productivity. The test menu is comprised of an extensive range of diagnostic reagents including routine chemistry, specific proteins, lipids, therapeutic drugs, drugs of abuse, antioxidants, and diabetes testing with over 113 tests available.

Randox, www.rsleads.com/906ml-157

Capillary separation



The Sebia CAPILLARYS 3 TERA provides high resolution capillary separation for HbA1c, serum proteins, serum immunofixation by capillary (immunotyping),

and hemoglobins. The fully automated CAPILLARYS 3 TERA offers proven technology, enhanced throughput, increased walk-away capabilities, and more flexibility for large volume laboratories. Hemoglobin now available. **Sebia www.rsleads.com/906ml-158**

Immunoassay and clinical chemistry solution

The Atellica Solution is a flexible immunoassay and clinical chemistry solution featuring patented bi-directional magnetic sample-transport technology. The transport technology, together with a multi-camera vision system, intelligent sample routing, and automatic quality control and calibration capabilities, gives labs independent control over every sample to speed patient results to clinicians. Atellica Solution can handle more than 30 sample container types including pediatric and tube top sample cups that can be aspirated from the primary tube. Using the same reagents and consumables across different analyzer configurations, laboratories can streamline inventory control and deliver consistent patient results no matter where they are tested.



Siemens, www.rsleads.com/906ml-159

Five-part differential hematology analyzer



The BC-5390 is a five-part differential hematology analyzer with built-in autoloader and a single closed tube sample mode. The hemoglobin analysis is performed using cyanide-free reagent. The analyzer processes up to 60 samples per hour and stores up to 100,000 results with histograms and Scattergram. The barcode reader and optional LIS connectivity enable seamless sample data transmission. Nearly all scheduled maintenance procedures are automated by touch buttons. The intuitive software enhances workflow efficiency and provides operators with a pleasant user experience. **Mindray, www.rsleads.com/906ml-160**

CHROMagar™ StrepA

**Specific to Group A
Streptococci**

**Easy to read
in orange colonies**

**Forget about
Blood Agar + Bacitracin!**

CHROMagar™
The Chromogenic Media Pioneer


Distributed in the U.S.A by :
DRG
www.drg-international.com

**Visit us at Booth 846
ASM 2019**

Ref.: SP372 (5L pack) - SP372-25 (25L pack)

CHROMagar is a trademark created by Dr A. Rambach

NO STOCK PHOTOS.
REAL STUDENTS.
REAL LABORATORIANS.
REAL...



AUTHENTIC LEARNING FROM AN ONLINE EXPERIENCE.
LEARN FROM THE PIONEERS OF ONLINE CLINICAL
LABORATORY SCIENCE EDUCATION. DISCOVER OUR
ONLINE GRADUATE AND CERTIFICATE PROGRAMS IN
BIOMEDICAL LABORATORY DIAGNOSTICS AND
ACCELERATE YOUR CAREER.

LEARN MORE

BLD.NATSCI.MSU.EDU/ONLINE-EDUCATION

MICHIGAN STATE
UNIVERSITY

NEW Unistik® Pro now available!

Featuring a syringe-like grip and a push-button design, Unistik® Pro offers a reliable blood sampling solution that's ergonomic, intuitive and affordable.

Owen Mumford

The intelligent analyzer

GEM® Premier™ 5000 blood gas system with iQM®2 assures quality before, during and after every sample in lab and POC testing—for improved patient care. All-in-one, multi-use cartridge offers advanced simplicity.

Instrumentation Laboratory

Enzymatic Fructosamine

Fructosamine, an early indicator of diabetic control, has a short lifespan reflecting average blood glucose levels from the previous 2 to 3 weeks. Randox offers instrument-specific applications for various biochemistry analyzers.

Randox Laboratories

Beckman Coulter Early Sepsis Indicator

With the potential to revolutionize emergency department sepsis identification, the Early Sepsis Indicator by Beckman Coulter is a new hematological biomarker helping physicians more

confidently assess sepsis or the risk of sepsis in adult patients.

Beckman Coulter

The BioFire® FilmArray® Pneumonia Panel

The BioFire Pneumonia Panel identifies 33 clinically relevant targets from sputum (including endotracheal aspirate) and bronchoalveolar lavage (including mini-BAL) samples. For 15 of the bacteria, the BioFire Pneumonia Panel provides semi-quantitative results.

BioFire Diagnostics

ALCOR Scientific proudly presents the miniiSED™

The miniiSED™ is a single position, fully automated ESR analyzer that works directly from the primary EDTA tube and produces an ESR result in 15 seconds. The miniiSED™ is half the size of the iSED® making it the ideal ESR analyzer for small laboratories, POLs and emergency clinics.

ALCOR Scientific

Bio-Rad launches AMH Control

Liquichek AMH Control is a dedicated Anti-Mullerian Hormone (AMH) control designed to meet the increasing demand for a liquid, independent, assayed quality control for AMH blood tests used primarily in fertility/*In Vitro* Fertilization clinics.

Bio-Rad Laboratories

Freelite: serum free light chain testing

Freelite is the only sFLC test FDA cleared for diagnosis and monitoring of Multiple Myeloma and AL Amyloidosis. Recommended by name in the International Myeloma Working Group guidelines, Freelite is internationally renowned for its analytical and clinical sensitivity.

Binding Site, Inc.

Characterize Microsatellite Instability (MSI) Status



The MSI Analysis System is a sensitive, multiplexed PRC-based assay that detects changes in the microsatellite marker sequences and provides evidence for MMR dysfunction. For Research Use

Only. Not for Use in Diagnostic Procedures.

Promega Corporation

Thermo Scientific MAS Quality Controls



Optimize lab performance and reduce spending with quality controls offering open vial stability, ready-to-use design, and extended shelf life. Thermo Scientific LabLink™ xL real-time software offers instant updates for faster troubleshooting.

Thermo Fisher Scientific

Prime Plus® critical care blood gas analyzer



Stat Profile Prime Plus is a comprehensive, whole blood critical care analyzer with 20 measured tests and 32 calculated results in a simple, compact, maintenance-free device. Test menu includes blood gases, electrolytes, metabolites, and co-oximetry.

Nova Biomedical

Is it HSV or is it VZV?



simplex virus type 1, type 2 and Varicella-zoster virus in 60 minutes.

Remove the uncertainty in lesion identification with Solana HSV 1+2/VZV, a multiplex *in-vitro* diagnostic test that detects and differentiates Herpes

Quidel

INDEX OF ADVERTISERS

Advertiser	URL	Page
ALCOR Scientific	www.alcorscientific.com	23
American Proficiency Institute	www.api-pt.com	3
AstraZeneca.....	www.azoncologyid.com	15
Audit MicroControls.....	www.auditmicro.com	IFC
Beckman Coulter	www.BeckmanCoulter.com/ami	11
Binding Site	www.bindingsite.com	29
BioFire Diagnostics	www.biofiredx.com	BC
Bio-Rad Laboratories	qcnet.com/serumindices	13
DiaSorin Molecular	www.molecular.diasorin.com	IBC
DRG International.....	www.drg-international.com	40
ELLKAY.....	www.ellkay.com	27
Hologic - Total Health	www.PantherFusion.com	19
Instrumentation Laboratory - Acute Care	www.instrumentationlaboratory.com	31
Kamiya Biomedical	www.k-assay.com/MLO.php	33
Michigan State University	www.bld.natsci.msu.edu/online-education	41
Nova Biomedical	www.novabiomedical.com	35
Owen Mumford	www.owenmumford.com/us	17
Polymedco	www.pathfast.com	22
Polymedco	www.polymedco.com	39
Promega.....	www.promega.com/MSIassay	21
Quidel.....	bit.ly/2G2Qzfc	1
Randox Laboratories.....	www.randox.com/rxseries	5
Thermo Fisher Scientific.....	www.thermofisher.com/MASproductivity	25

This index is provided as a service. The publisher does not assume liability for errors or omissions.



A conversation with Lior Hod, ELLKAY's Beekeeper, Chief Culture Officer, Founder & President

ELLKAY was founded in 2002. Can you tell us the story behind its foundation?

Kamal Patel, ELLKAY's CEO, and I started ELLKAY in the basement of my home in 2002, where we started building demographic bridges for laboratories. It all started with a soda business... I started working with Kamal at a company back in 1997 as Senior Developers and we shared an office. In fact, we still share an office. We thrived working as a team on complex projects. During our time there, the company increased the price of soda from \$1.00 to \$1.10. We decided to put a small fridge in our office and fill it with sodas. We advertised 50¢ sodas and everyone in the company started coming to our office for them. We added other items: water, candy, chips, ice cream, and free watermelon on Thursdays. We made \$3,000 profit that year... all of which went to charity. We loved it and it felt great. So, we decided to start our company with the same energy and culture as our little "side venture." My wife Janet came up with the company name ELLKAY after our first name initials ELL for Lior and KAY for Kamal.

What kept you occupied prior to 2002?

I started my career in the early '90s in the clinical laboratory testing space as a consultant for a company called MetPath Laboratory (known today as Quest Diagnostics). During my time at MetPath, I helped design and build one of the first electronic lab order and results management systems, called CCLink. I then went to the 3M Health Information Division, and they were just starting out with healthcare. I was one of the lead developers for their All Patient Refined Diagnosis Related Groups (APR DRG) solution.

How did the acquisition of the CareEvolve Laboratory Portal and Connectivity Platform benefit ELLKAY and its customers?

CareEvolve was a great fit for ELLKAY—both companies have a high focus and strength in technology and innovation. While ELLKAY already had a good footprint in the market before the acquisition, this allowed us to offer more advanced laboratory outreach solutions to those markets and expand our level of service and partnership in the hospital

market. More importantly, it increased our whitespace for all our other product lines (non-lab) in the hospital market. I feel it was a good transaction for both sides.

Please explain how ELLKAY is a "client-first" company.

At ELLKAY, we are very proud of our 'client-first' focus. What it means is that we value our clients and recognize that strong relationships are the foundation for a strong company. Our customer-centric approach drives results. We understand that every business is different and there is no 'one size fits all' model, therefore we work with our clients to identify the best strategy for their success, while providing innovative, scalable solutions, and unparalleled service.

Your title has Chief Culture Officer in it. What does this mean at ELLKAY?

I take this title very seriously. I view my life as one long journey, forming friendships along the way. Due to ELLKAY's growth, we purchased our new building in 2017. We moved from a 13,000-square-foot building to one with 74,000 square feet. I personally participated in designing and building the best workplace I could think of. We went with an open floorplan design to encourage collaboration and innovation, glass office partitions, standing corner desks, LED lights, gaming chairs, and a whole lot more.

Since the time we started the business in my basement, we have always paid for lunch for our employees. We also provide cold drinks, the best coffee, bagels, fresh fruits, fresh-baked cookies, ice cream, and beer on tap. I like to create an environment that rewards the hard work of our employees. I believe that in creating an atmosphere that celebrates their dedication, it encourages them to not only have fun, but also strive for excellence.

Receiving ELLKAY honey is always a pleasant surprise! I heard you tend honeybees on the roof of ELLKAY's HQ.

Tell me how this all started. In early 2015, Kamal and I were driving for a meeting with our product design team. That morning, I had happened to read an article in the *New York Times* about how the honeybees were dying throughout the country. With it



fresh in my mind, I brought up the subject and mentioned how I had always wanted to raise honeybees and harvest the honey for our friends and clients. The group loved the idea, so I contacted my beekeeper friend and the process started.

We owned our building, so we were able to set up six hives (which initially housed 36,000 bees) on our flat roof. Everyone volunteered to build the hives and care for them and within months, the bees multiplied to more than 300,000. When we moved offices, we also (carefully) relocated the hives and its residents. We now have 16 active hives and we produce and package our own honey on premises. The honey demand is so high that we are in the process of expanding to a remote location in upstate NY.

Besides tending to the honeybees, what do you like to do off-the-clock?

My passion is basketball. We are a big basketball family; I played college ball with my brother at Yeshiva University and we are still currently ranked as No. 2 and No. 3 for scoring. I am also blessed that my three boys also played for the same school. In fact, all three played in the same game in 2017, marking the first time in NCAA Division III men's basketball history that three siblings from the same team were on the floor at the same time. I am a proud grandfather to six-month-old twins. I'm also fortunate that two of my children work with me at ELLKAY, so I get to spend time with them and mentor them regularly. 🍯

Read the full interview at mlo-online.com.

**Now FDA
Cleared**

Simplexa™ Bordetella Direct Kit

Simple and Reliable Bordetella Testing

Direct detection and differentiation of
Bordetella pertussis and *Bordetella parapertussis*

- **Broad coverage for your testing needs:**
Detect both *B. pertussis* and *B. parapertussis*.
- **True, sample-to-answer workflow:**
CLIA moderate complexity without DNA extraction for results in about an hour.
- **Sample type:**
Nasopharyngeal swabs.
- **Comprehensive respiratory testing:**
Our Simplexa™ assays ensure quality Flu A/B & RSV, Group A Strep, and Bordetella testing.

Request a Trial Today

www.molecular.diasorin.com

+1 (562) 240-6500



**DiaSorin
Molecular**

The quality of treatment starts with diagnosis.

CAPAD0119

Simplexa is a trademark of DiaSorin Molecular LLC. Reg. US. Pat. & Tm. Off.
Product availability subject to required regulatory approvals.

Crack pneumonia cases faster.

Get fast, comprehensive results with the BioFire® FilmArray® Pneumonia Panel.

Respiratory infections can arise from a variety of pathogens. The BioFire Pneumonia Panel utilizes a syndromic approach—simultaneously testing for the most likely organisms to cause similar signs and symptoms. Our simple, rigorous test identifies specific pathogens—as well as levels of organism present in a given sample—all in about one hour. The BioFire Pneumonia Panel drastically improves turnaround time to organism identification, delivering fast, comprehensive results that ultimately aid in diagnosis.

Learn more at biofiredx.com

The BioFire Pneumonia Panel

Bacteria (semi-quantitative)

Acinetobacter calcoaceticus baumannii complex
Enterobacter cloacae complex
Escherichia coli
Haemophilus influenzae
Klebsiella aerogenes
Klebsiella oxytoca
Klebsiella pneumoniae group
Moraxella catarrhalis
Proteus spp.
Pseudomonas aeruginosa
Serratia marcescens
Staphylococcus aureus
Streptococcus agalactiae
Streptococcus pneumoniae
Streptococcus pyogenes

Atypical Bacteria (qualitative)

Chlamydia pneumoniae
Legionella pneumophila
Mycoplasma pneumoniae

Viruses (qualitative)

Adenovirus
Coronavirus
Human Metapneumovirus
Human Rhinovirus/Enterovirus
Influenza A
Influenza B
Parainfluenza virus
Respiratory Syncytial virus

Resistance Markers

Carbapenemase
IMP
KPC
NDM
Oxa48-like
VIM
ESBL
CTX-M
MRSA
mecA/C and *MREJ*



Syndromic Testing: The Right Test, The First Time.

